apomorphine has been researched along with levodopa in 680 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 312 (45.88) | 18.7374 |
| 1990's | 161 (23.68) | 18.2507 |
| 2000's | 102 (15.00) | 29.6817 |
| 2010's | 73 (10.74) | 24.3611 |
| 2020's | 32 (4.71) | 2.80 |
| Authors | Studies |
|---|---|
| Agnati, L; Dafeldecker, WP; Fuxe, K; Guarino, J; Kosersky, DS; Neumeyer, JL; Reinhard, JF | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cox, B; Kastin, AJ; Schnieden, H | 1 |
| Quik, M; Sourkes, TL | 2 |
| Carroll, BJ; Curtis, GC; Kokmen, E | 1 |
| Donatelli, L | 1 |
| Anand, M; Bhargava, KP; Gupta, GP | 1 |
| Schreiber, V | 1 |
| Hungerbühler, JP; Regli, F | 1 |
| Rinne, UK | 1 |
| Hagino, K; Ikeda, M; Watanabe, H; Watanabe, K | 1 |
| Adams, WL; Barnes, CD; Fung, SJ | 1 |
| Costentin, J | 1 |
| Allikmets, LH; Zharkovsky, AM | 1 |
| Carvey, PM; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Desiles, M; Puech, AJ; Rips, R | 1 |
| Ahlenius, S; Berggren, U; Engel, J; Tallstedt, L | 1 |
| Crossman, AR; Sambrook, MA; Slater, P | 1 |
| Hicks, PB; Samorajski, T; Smith, RC; Strong, JR | 1 |
| Brown, RM; Brozoski, TJ; Goldman, PS; Rosvold, HE | 1 |
| Nistico', G; Stephenson, JD | 1 |
| Bailey, RC; Bracs, PU; Jackson, DM | 1 |
| Akil, H; Liebeskind, JC | 1 |
| Tolosa, ES | 1 |
| Jacobs, BL; Ruimy, DD; Simon, SM; Trulson, ME | 1 |
| Darwish, SA; Furman, BL | 1 |
| Jahodová, J; Pribyl, T; Schreiber, V | 1 |
| Arushanian, EB; Avakian, RM | 2 |
| Carlson, HE; Goodlett, RE; Hershman, JM; Levy, CL; Sowers, JR; Tourtellotte, WW | 1 |
| Caraceni, T; Cocchi, D; Müller, EE; Panerai, AE; Parati, EA | 1 |
| Ljungberg, T; Ungerstedt, U | 2 |
| Dinnendahl, V; Gumulka, SW; Peters, HD; Schönhöfer, PS | 1 |
| Sicuteri, F | 1 |
| Carolei, A; Margotta, V; Palladini, G | 1 |
| Marais, C | 1 |
| Bédard, P; Dankova, J; Langelier, P; Poirier, LJ | 1 |
| Borison, RL; Diamond, BI | 1 |
| Ahlenius, S | 1 |
| Pohto, P | 2 |
| Lazarova, MB; Roussinov, KS | 1 |
| Georgiev, VP; Markovska, VL; Petkova, BP | 1 |
| Fukuda, N; Miyamoto, M; Nagai, Y; Nagawa, Y; Narumi, S; Shima, T | 1 |
| Creese, I; Iversen, SD | 2 |
| Finn, BW; Mendez, JS | 1 |
| Bogaert, MG; Willems, JL | 1 |
| Cox, B; Tha, SJ | 1 |
| Laverty, R | 1 |
| Dent, R; Guyda, H; Tolis, G | 1 |
| Gale, CC; Garcia, JF; Mixter, RC; Ruch, W; Russell, RM | 1 |
| Lippmann, W; Pugsley, TA | 1 |
| Commissiong, JW; Sedgwick, EM | 1 |
| Lazarova, M; Roussinov, K | 1 |
| Podolec, Z; Serwońska, M; Sieradzki, J; Szezklik, A | 1 |
| Halvorsen, KA; Martensen-Larsen, O | 1 |
| Ohlin, H; Stenberg, P; Wadstein, J | 1 |
| Cotzias, GC; Miller, ST; Papavasiliou, PS; Rosal, VL | 1 |
| Brown, WA; Mueller, B | 1 |
| Brambilla, F; Guastalla, A; Maffei, C; Nobile, P; Ponzano, M; Rovere, C; Scarone, S | 1 |
| Lai, C; Tolosa, ES | 1 |
| Agid, Y; Barroche, G; Bonnet, AM; Javoy-Agid, F; Kato, G; Lhermitte, F; Pollak, P; Signoret, JL | 1 |
| Anlezark, GM; Marsden, CD; Meldrum, BS | 1 |
| Maître, L; Waldmeier, PC | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Passerini, D; Trabucchi, M | 1 |
| Brunswick, D; Frazer, A; Maany, I; Mendels, J | 1 |
| Arushanian, EB; Avakian, RM; Kozlov, VKh; Pergaev, AP | 1 |
| List, SJ; Seeman, P | 1 |
| Bednarczyk, B; Podolec, Z; Szczeklik, A; Vetulani, J | 1 |
| Berrios, N; Marshall, JF | 1 |
| Asano, T; Matsumoto, Y; Mimura, Y; Mino, S; Nishimoto, A; Ohmoto, T; Yoshimura, Y | 1 |
| Dadkar, VN; Dahanukar, SA; Sheth, UK | 1 |
| Atkins, HL; Som, P | 1 |
| Ankov, V; Georgiev, V; Markovska, V | 1 |
| Carchedi, F; Casacchia, M; Di Ceglie, M; Meco, G | 1 |
| Podol'skiĭ, IIa | 1 |
| Allikmets, LKh; Vasar, EE; Zharkovskiĭ, Am | 1 |
| Goetz, C; Klawans, HL; Nausleda, PA; Weiner, WJ | 1 |
| Ezrin-Waters, C; Seeman, P | 1 |
| Martin, JR; Quock, RM | 2 |
| Doroski, D; Ginos, JZ | 1 |
| Uemura, H | 1 |
| Bohannon, NV; Forsham, PH; Gerich, JE; Karam, JH; Lorenzi, M; Tsalikian, E | 1 |
| Banovac, K; Petek, M; Sekso, M; Solter, M; Vizner, B | 1 |
| Agrin, R; La Rossa, JT; Melby, JC | 1 |
| Goetz, C; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Barbeau, A; Bélanger, F; Butterworth, RF | 1 |
| Angrist, B; Paquin, J; Rotrosen, J | 1 |
| Johnels, B; Steg, G; Ungerstedt, U | 1 |
| Green, AR | 1 |
| Agnati, LF; Everitt, BJ; Fredholm, BB; Fuxe, K; Gustafsson, JA; Jonsson, G; Ogren, SO | 1 |
| Bieger, D; Hockman, CH; Weerasuriya, A | 1 |
| Angrist, B; Clark, C; Gershon, S; Halpers, FS; Rotrosen, J; Sachar, EJ | 1 |
| Bucher, B; Doepfner, W; Jaton, AL; Marbach, P; Ruch, W | 1 |
| Gessa, GL; Mereu, G; Paglietti, E; Quarantotti, BP | 1 |
| Strömbom, U; Svensson, TH | 1 |
| Farley, IJ; Hornykiewicz, O; Lee, T; Rajput, A; Seeman, P | 1 |
| Chung, PM; Lee, HK; Wang, SC | 1 |
| Ganong, WF; Grumbach, MM; Holland, FJ; Kaplan, SL; Richards, GE | 1 |
| Pietoń, R; Podolec, Z; Serwońska, M; Sieradzki, J; Szczeklik, A | 1 |
| Pepeu, G | 1 |
| Breese, GR; Hollister, AS; Mueller, RA | 1 |
| Ernst, AM | 1 |
| Barry, VC; Klawans, HL | 1 |
| Fleisher, LN; Glick, SD; Jerussi, TP | 1 |
| Poirier, LJ | 1 |
| Hoyte, KM; Martin, JB | 1 |
| Bartholini, G; Haefely, W; Pletscher, A | 1 |
| Anagnoste, B; Battista, AF; Goldstein, M; Ogawa, M | 1 |
| Costentin, J; Marçais, H; Protais, P; Schwartz, JC | 1 |
| Ahlenius, S; Engel, J | 1 |
| Glick, SD; Jerussi, TP | 1 |
| Grahame-Smith, DG; Green, AR; Heal, DJ; Kelly, PH | 1 |
| Angrist, BM; Gershon, S; Halpern, FS; Rotrosen, J; Sachar, EJ | 2 |
| Heffner, TG; Stricker, EM; Zigmond, MJ | 2 |
| Bieger, D; Giles, SA; Hockman, CH | 1 |
| Cuparencu, B; Sandor, V | 1 |
| Agnati, L; Fuxe, K; Hökfelt, T; Löfstöm, A | 1 |
| Bartolini, A; Mantovani, P; Pepeu, G | 1 |
| Bunney, WE | 1 |
| Clouet, DH; Iwatsubo, K | 1 |
| Marshall, JF; Ungerstedt, U | 1 |
| Gardner, EL; Glusman, N; Logan, N; Marotta, RF; Potegal, M | 1 |
| Davis, JM; Frohman, LA; Pandey, G; Smith, RC; Tamminga, CA | 1 |
| Baudry, M; Martres, MP; Schwartz, JC | 1 |
| Johnson, AM; Loew, DM; Vigouret, JM | 1 |
| Avakian, RM | 1 |
| Nygren, LG; Olson, L | 1 |
| Mora, F; Rolls, ET; Sanguinetti, AM; Sweeney, KF | 1 |
| Lippman, W; Pugsley, TA | 1 |
| Dolphin, AC; Jenner, P; Marsden, CD | 1 |
| Couper, GS; Huprikar, SV; Mellow, AM; Moody, RR; Zeller, EA | 1 |
| Pakszys, W | 1 |
| Argiolas, A; Di Chiara, G; Gessa, GL; Porceddu, ML; Vargiu, L | 1 |
| Cotzias, GC; Ginos, JZ; Papavasiliou, PS | 1 |
| Debono, AG; Marsden, CD; Parkes, JD | 1 |
| Gräf, HJ; Horowski, R | 1 |
| Fujiwara, M; Inoue, K; Ueki, S | 1 |
| Lippmann, W; Pugsley, T | 1 |
| Costall, B; Naylor, RJ | 2 |
| Dickey, RP; Stone, SC | 1 |
| Bastard, J; Chanelet, J; Emile, J; Truelle, JL | 1 |
| Baldessarini, RJ | 1 |
| Bell-Midura, M; Cotzias, GC; Mendez, JS; Papavasiliou, PS; Tolosa, ES | 1 |
| Boucher, R; Dankova, J; Poirier, LJ | 1 |
| Klawans, HL; Margolin, DI | 1 |
| Gudelsky, GA; Moore, KE; Thornburg, JE | 1 |
| Cotzias, GC; Dahl, K; Finn, BW; Mendez, JS | 1 |
| De la Vega, CE; Friesen, HG; Lal, S; Martin, JB | 1 |
| Moore, KE; Thornburg, JE | 1 |
| Butcher, LL; Hodge, GK | 1 |
| Crossett, P; Dana, N; Klawans, HL | 1 |
| Barnett, A; Goldstein, J | 1 |
| Crosset, P; Dana, N; Klawans, HL; Margolin, DI | 1 |
| Kuschinsky, K | 1 |
| Buckett, WR; Shaw, JS | 1 |
| Barnett, A; Goldstein, JM; Malick, JB | 1 |
| Jenner, P; Marsden, CD | 1 |
| Sparber, SB; Takemori, AE; Tulunay, FC | 1 |
| Paalzow, G; Paalzow, L | 1 |
| Agnoli, A; Carolei, A; Cerbo, R; Meco, G; Ruggieri, S; Zamponi, A | 1 |
| Dandiya, PC; Kulkarni, SK | 1 |
| Luchins, D | 1 |
| Marsden, CD; Pycock, C; Tarsy, D | 1 |
| Fujiwara, M; Ibii, N; Inoue, K; Kataoka, Y; Ueki, S | 1 |
| Cotzias, GC; Tang, LC | 1 |
| Costall, B; Kelly, DM; Naylor, RJ | 1 |
| Deffond, D; Durif, F; Eschalier, A; Tournilhac, M | 1 |
| Chen, LJ; Guo, X; Jin, GZ; Wang, QM | 1 |
| Fredow, G; Löscher, W | 1 |
| Quinn, NP; Steiger, MJ | 1 |
| Grandas, F; Laguna, J; Luquin, MR; Martinez-Lage, JM; Obeso, JA; Vaamonde, J | 1 |
| Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J | 1 |
| Bohmaker, K; Bordi, F; Meller, E | 1 |
| Kohsaka, S; Nagatsu, T; Tsuzaki, N; Uchida, K | 1 |
| Broussolle, E; Marion, MH; Pollak, P | 1 |
| Ekman, A; Eriksson, E | 1 |
| Buonamici, M; Cervini, MA; Maj, R; Mantegani, S; Rossi, AC | 1 |
| Blunt, SB; Jenner, P; Marsden, CD | 3 |
| Marsden, CD; Quinn, NP; Steiger, MJ | 1 |
| Arnold, G; Gasser, T; Oertel, WH; Schwarz, J; Trenkwalder, C | 1 |
| Colosimo, C; Daniel, SE; Hughes, AJ; Kleedorfer, B; Lees, AJ | 1 |
| Lees, AJ; Merello, M | 1 |
| Levivier, M; Przedborski, S | 1 |
| Adba, MA; Aranda, B; Cramer, P | 1 |
| Humphreys, TM; Schmidt, CJ; Sorensen, SM; Taylor, VL | 1 |
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K; Trenkwalder, C | 1 |
| Court, J; Godoy, J; Valenzuela, R | 1 |
| Gancher, ST; Grandas, F; Lera, G; Nutt, JG; Obeso, JA; Rodriguez, M | 1 |
| Chen, S | 1 |
| Bonuccelli, U; Corsini, GU; Muratorio, A; Piccini, P | 1 |
| Jenkins, JR; Pearce, JM | 1 |
| de Saint Victor, JF; Gervason, CL; Perret, J; Pollak, P | 1 |
| Boyce, S; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Castro, R; Rodriguez, M | 1 |
| Abbott, RJ; D'Costa, DF; Millac, PA; Pye, IF | 1 |
| Carey, RJ | 1 |
| Joyce, JN; Neal, BS | 1 |
| Gervason, CL; Pollak, P | 1 |
| Baronti, F; Chase, TN; Conant, K; Davis, TL; Giuffra, M; Heuser, IJ; Mouradian, MM | 1 |
| Blunt, S; Jenner, P; Marsden, CD | 1 |
| Graham, SJ; Higgins, BM; Morris, JG; Panegyres, PK; Williams, BK | 1 |
| Gancher, ST; Nutt, JG; Woodward, WR | 2 |
| Hughes, AJ; Lees, AJ; Stern, GM | 4 |
| Gilhus, NE | 1 |
| Davis, A; Jenner, P; Marsden, CD | 1 |
| Haba, K; Mizukawa, K; Ogawa, N; Sato, H | 1 |
| Cho, F; Kanazawa, I; Kimura, M; Murata, M; Tanaka, Y | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Elazar, Z; Ganchrow, D; Korczyn, AD; Paz, M; Paz, Z; Rabinowitz, R | 1 |
| Kleedorfer, B; Lees, AJ; Milroy, C; Ryan, R; Stern, GM; Turjanski, N | 1 |
| Kondo, T; Narabayashi, H; Nishi, K | 1 |
| Abbott, RJ; Millac, PA; Ray-Chaudhuri, K | 1 |
| Kleedorfer, B; Lees, AJ; Stern, GM | 1 |
| Bishop, S; Hughes, AJ; Lees, AJ; Stern, GM | 1 |
| Quinn, N | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ | 1 |
| Ceresoli, G; Groppetti, A; Mandelli, V; Parenti, M | 1 |
| Carboni, S; Gessa, GL; Pani, L; Portas, CM; Rossetti, ZL | 1 |
| Archer, T; Fredriksson, A; Sundström, E | 1 |
| Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM | 2 |
| Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL | 1 |
| Benabid, AL; Champay, AS; Gaio, JM; Hommel, M; Perret, J; Pollak, P | 1 |
| Jansen, EN; van Laar, T | 1 |
| Frankel, JP; Hughes, A; Lees, AJ; Stern, GM | 1 |
| Boucher, B; Gancher, ST; Gliessman, P; Nutt, JG; Woodward, WR | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 2 |
| Etemadzadeh, E; Kaakkola, S; Koskinen, L | 1 |
| Agnoli, A; Carta, A; Ruggieri, S; Stocchi, F | 1 |
| Grandas, F; Obeso, JA | 1 |
| Czyrak, A; Maj, J; Mogilnicka, E | 1 |
| Benabid, AL; Champay, AS; Hommel, M; Perret, JE; Pollak, P | 1 |
| Imazu, Y; Kobayashi, K; Shohmori, T | 1 |
| Agid, Y; Chase, TN; Engber, TM; Juncos, JL; Ploska, A; Raisman, R; Susel, Z; Thibaut, F | 1 |
| Boucher, B; Gancher, ST; Nutt, JG; Woodward, WR | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Beart, PM; Cook, CJ; Hashizume, M; Jackson, DM; Tabar, J | 1 |
| Maayan, ML; Sellitto, RV; Volpert, EM | 1 |
| Briley, M; Chopin, P; Couzinier, JP; Stenger, A | 1 |
| Cassel, G; Persson, SA; Sellström, A | 1 |
| Flauto, C; Groppetti, A; Parati, E; Parenti, M; Vescovi, A | 1 |
| Fitten, J; Kling, AS; Kodama, CK; Menon, MK | 1 |
| Fujiwara, M; Kamiya, H; Ono, N; Saito, R | 1 |
| Grandas, F; Martínez-Lage, JM; Obeso, JA; Rosario Luguin, M; Vaamonde, J | 1 |
| Bohmaker, K; Friedhoff, AJ; Goldstein, M; Meller, E; Namba, Y | 1 |
| Kempster, PA; Lees, AJ; Stern, GM; Stibe, CM | 1 |
| Crichton, P; Frankel, JP; Kempster, PA; Lees, AJ; Shorvon, P | 1 |
| Flauto, C; Groppetti, A; Parati, E; Parenti, M; Rusconi, L; Vescovi, A | 1 |
| Goldstein, M; Lloyd, KG; Willigens, MT | 1 |
| Barkov, NK; Machula, AI | 1 |
| Wambebe, C | 1 |
| Abe, Y; Kisara, K; Tadano, T; Yonezawa, A | 1 |
| Casas, M; Cobos, A; Ferre, S; Garcia, C; Grau, JM; Jane, F | 1 |
| Boismare, F; Daoust, M; Moore, N; Saligaut, C | 2 |
| Braz, S; Ferreira, TM; Silveira Filho, NG; Troncone, LR; Tufik, S | 1 |
| Kantak, KM; Miczek, KA | 1 |
| Holland, OB; Kennedy, B; Lake, CR; Murphy, D; Ziegler, MG | 1 |
| Bankiewicz, KS; Chiueh, CC; Doppman, JL; Jacobowitz, DM; Kopin, IJ; Oldfield, EH | 1 |
| Gaio, JM; Hommel, M; Mallaret, M; Perret, J; Pollak, P | 1 |
| Herbster, G; Koller, WC | 1 |
| Gancher, ST; Nutt, JG | 1 |
| Ahlenius, S; Criborn, CO; Henriksson, C; Hillegaart, V | 1 |
| Grandas, F; Luquin, MR; Martinez Lage, JM; Obeso, JA; Vaamonde, J | 1 |
| Adler, CH; Bohmaker, K; Friedhoff, AJ; Goldstein, M; Helmer-Matyjek, E; Meller, E | 1 |
| Czuczwar, SJ; Löscher, W | 1 |
| Aizenstein, ML; de-Lucia, R; Scavone, C; Steinschreiber, S | 1 |
| Cohen, O; Globus, M; Melamed, E; Rosenthal, J; Uzzan, A | 1 |
| Farel, PB; McClellan, AD | 1 |
| Hardie, RJ; Lees, AJ; Stern, GM | 1 |
| Liskowsky, DR; Potter, LT | 1 |
| Chang, JP; Cook, AF; Marchant, TA; Nahorniak, CS; Peter, RE | 1 |
| Boiadzhieva, N; Ovcharov, R; Zakharieva, B | 1 |
| Watanabe, H | 1 |
| Hietala, J; Koulu, M; Scheinin, M; Syvälahti, E | 1 |
| Artieda, J; Luquin, MR; Martínez Lage, JM; Obeso, JA; Tuñón, T | 1 |
| King, TS; Morgan, WW; Steger, RW | 1 |
| Davis, BM; Davis, KL; Horvath, TB; Johns, CA; Levy, MI; Mathé, AA; Mohs, RC; Rothpearl, AB | 1 |
| Aleksić, J; Geber, J; Gjuris, V; Ivanović, D; Marović, A; Reić, P; Sikirić, P; Suchanek, E | 1 |
| Fayle, P; Jackson, DM; Jenkins, OF; Lafferty, PA | 1 |
| Grewaal, DS; McGeer, EG; McGeer, PL | 1 |
| Antonaccio, MJ; Robson, RD | 1 |
| Cotzias, GC; Dunn, M; Tang, LC | 1 |
| Anagnoste, B; Battista, AF; Fuxe, K; Goldstein, M; Miyamoto, T | 1 |
| Boal, D; Le Brun, Y; Lieberman, A; Zolfaghari, M | 1 |
| Cotzias, GC; Mena, I; Mendez, J; Papavasiliou, PS | 1 |
| Cotzias, GC; Mena, I; Papavasiliou, PS | 1 |
| Kadzielawa, K | 1 |
| Fechter, LD | 1 |
| Cotzias, GC | 1 |
| Ljungberg, T; Steg, G; Ungerstedt, U | 1 |
| Bianchine, JR; Sunyapridakul, L | 1 |
| Andén, NE; Engel, J | 1 |
| Burton, K; Calne, DB | 1 |
| Chiu, S; Mishra, RK | 1 |
| Andreeva, OG; Korovin, KF; Ostroumova, MN; Schelkunov, EL | 1 |
| Tufik, S | 1 |
| Gonzalez, JP; Littler, ME; Sewell, RD | 1 |
| Calderazzo, L; Cepeda, C; Naquet, R; Stutzmann, JM; Valin, A | 1 |
| Jackson, DM; Miller, LP; Walters, JR | 1 |
| German, DC; Matthews, RT; McMillen, BA; Sanghera, MK; Shepard, PD | 1 |
| Algeri, S; Carolei, A; Ferretti, P; Gallone, C; Palladini, G; Venturini, G | 1 |
| Feenstra, MG; Goedemoed, JH; Horn, AS; Rollema, H | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 1 |
| Casey, DE; Gerlach, J | 1 |
| Feigenbaum, JJ; Fishman, RH; Klawans, HL; Yanai, J | 1 |
| Achilli, G; Algeri, S; Cimino, M; Lipartiti, M; Perego, C; Ponzio, F; Vantini, G | 1 |
| Balsara, JJ; Chandorkar, AG; Gada, VP; Nandal, NV | 1 |
| Galliani, G; Glässer, A; Restelli, A; Rosina, R | 1 |
| Kurako, IuL; Volianskiĭ, VE | 1 |
| Lee, MC | 1 |
| Crisp, T; Trulson, ME | 1 |
| Jin, GZ; Li, JH; Wang, XL; Yu, LP | 1 |
| Groĭsman, SD; Karevina, TG; Khokholia, VP | 1 |
| Czuczwar, SJ; Kleinrok, Z; Kozicka, M | 1 |
| Schorderet, M; Sovilla, JY | 1 |
| Laakso, K; Laihinen, A; Lönnberg, P; Rinne, JK; Rinne, JO; Rinne, UK | 1 |
| Globus, M; Melamed, E | 1 |
| Kashiwabara, K | 1 |
| Koulu, M; Lammintausta, R | 2 |
| Gamaniel, K; Osuide, G; Wambebe, C | 1 |
| Osuide, G; Wambebe, C | 1 |
| Schmidt, WJ | 1 |
| Ackman, D; Etienne, P; Kiely, ME; Lal, S; Thavundayil, JX | 1 |
| Cooper, DR; Fleminger, S; Hall, MD; Jenner, P; Marsden, CD; Rupniak, NM | 1 |
| Christie, MJ; Gregory, P; Jackson, DM; Jenkins, OF; Malor, R | 1 |
| Brianda, S; Delitala, G; Maioli, M; Mannelli, M; Pacifico, A; Palermo, M | 1 |
| Bergmann, KJ; Clough, CG; Yahr, MD | 1 |
| Baker, GB; Gutman, M; Vanderwolf, CH | 1 |
| Dahlström, S; Koulu, M; Lammintausta, R | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Berggren, U; Engel, J | 1 |
| Bailey, R; Crisp, E; Jackson, DM; Jenkins, O | 1 |
| Arruda, F; Campos, F | 1 |
| Bannet, J; Belmaker, RH; Globus, M; Lerer, B | 1 |
| Georgiev, V; Markovska, V | 1 |
| Atamer-Simşek, S; Keyer-Uysal, M; Koyuncuoğlu, H; Sağduyu, H | 1 |
| Cheung, BS; Money, KE | 1 |
| Carvey, P; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 2 |
| Dalphrase, F; DeFeudis, FV; Deniard, MJ; Grognet, A; Meignen, J; Roux, E | 1 |
| Broekkamp, CL | 1 |
| Freund, H; Koch, M; Lauterbach, H; Oettel, M | 1 |
| Pappas, BA; Robinson, TE; Vanderwolf, CH | 1 |
| McDevitt, JT; Setler, PE | 1 |
| Hedner, T; Lundborg, P | 1 |
| Agnati, LF; Fuxe, K | 1 |
| Pirke, KM; Spyra, B | 1 |
| Hefti, F; Melamed, E; Sahakian, BJ; Wurtman, RJ | 1 |
| Ikeda, M; Watanabe, H; Watanabe, K | 1 |
| Stewart, RM | 1 |
| Fang, VS | 1 |
| Atamer-Simşek, S; Keyer-Uysal, M; Koyuncuoğlu, H | 1 |
| Malarkey, WB; Tallo, D | 1 |
| Balldin, J; Granérus, AK; Lindstedt, G; Modigh, K; Wålinder, J | 1 |
| Korányi, L; Phelps, CP; Tamásy, V | 1 |
| Dregits, DP; Erinoff, L; Levine, TE; Seiden, LS | 1 |
| Stricker, EM; Zigmond, MJ | 1 |
| Nistico, G | 1 |
| Cannon, JG; Flynn, JR; Goodale, DP; Lee, T; Long, JP; Rusterholz, DB; Walsh, B | 1 |
| Bédard, PJ; Côté, PY; Grégoire, L; Parent, A; Roy, E | 1 |
| Agid, Y; Blin, J; Bonnet, AM; Durif, F; Vidailhet, M | 1 |
| Andrade, LA; Azevedo-Silva, SM; Borges, V; Ferraz, HB; Rocha, MS | 1 |
| Danhof, M; Jansen, EN; Neef, C; Roos, RA; van Laar, T | 1 |
| Corboy, DL; Sage, JI; Wagner, ML | 1 |
| Block, F; Clement, HW; Grote, C; Sontag, KH; Wesemann, W | 1 |
| Crossman, AR; Page, RD; Sambrook, MA | 1 |
| Bösch, MF; Ludin, HP | 1 |
| Bakheit, AM | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Baronti, F; Fabbrini, G; Lenzi, GL; Ruggieri, S | 1 |
| Hastie, IR; Mukherjee, D | 1 |
| Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Kaur, S; Starr, BS; Starr, MS | 1 |
| Basham, DA; Bohmaker, K; Goldstein, M; Meller, E | 1 |
| Gash, DM; Sakai, K | 1 |
| de Groat, WC; Roppolo, JR; Yoshiyama, M | 1 |
| Bräutigam, K; Morgenstern, R; Sohr, R | 1 |
| Kempster, PA; Lees, AJ | 1 |
| Gnanalingham, KK; Robertson, RG | 1 |
| Albani, C; Bächli, E | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW; Sohn, YH | 1 |
| Crossman, AR; Graham, WC; Sambrook, MA | 1 |
| Gurevich, V; Jiao, S; Wolff, JA | 1 |
| Carruba, MO; da Prada, M; Imhof, R; Nisoli, E; Scherschlicht, R; Tonello, C | 1 |
| Fouillet, N; Henry, P; Tison, F | 1 |
| Deffond, D; Dordain, G; Durif, F; Tournilhac, M | 1 |
| Aotsuka, A; Bravi, D; Chase, TN; Linfante, I; Metman, LV; Mouradian, MM; Sohn, YH | 1 |
| Lera, G; Luquin, MR; Obeso, JA; Rodriguez, M; Vaamonde, J | 1 |
| Helscher, RJ; Pinter, MM; Sattler, AP | 1 |
| Essink, AW; Jansen, EN; Neef, C; Oosterloo, S; Roos, RA; van Laar, T | 1 |
| Aranda, B; Cramer, P | 1 |
| Fernandez, W; Lees, AJ; Turjanski, N | 1 |
| Chollet, F; Marc-Vergnes, JP; Montastruc, JL; Rascol, A; Rascol, OJ; Sabatini, U | 1 |
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Baronti, F; Bramante, L; Monge, A; Ruggieri, S; Stefano, E; Stocchi, F; Viselli, F | 1 |
| Bösch, S; Kleedorfer, B; Poewe, W; Schelosky, L; Wagner, M | 1 |
| Bonuccelli, U; Corsini, GU; Del Dotto, P; Muratorio, A; Piccini, P; Rossi, G | 1 |
| Bishop, S; Fernandez, W; Hughes, AJ; Kleedorfer, B; Lees, AJ; Stern, GM; Turjanski, N | 1 |
| Bösch, S; Kreczy-Kleedorfer, B; Poewe, W; Wagner, M | 1 |
| Miranda, M; Saéz, D | 1 |
| Colosimo, C; Hughes, AJ; Lees, AJ; Merello, M; Sieradzan, K | 2 |
| Arnold, G; Eichhorn, TE; Gasser, T; Mai, N; Marquardt, C; Oertel, WH; Schwarz, J | 1 |
| Ahlskog, JE; Dewey, RB; Maraganore, DM; Matsumoto, JY | 2 |
| Bassi, A; Cicardi, MC; Loberti, M; Pierantozzi, M; Semprini, R; Stanzione, P; Traversa, R | 1 |
| Baas, H; Bürklin, F; Demisch, L; Fischer, PA; Harder, S; Stecker, K | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Durrieu, G; Llau, ME; Montastruc, JL; Rascol, O; Senard, JM; Tran, MA | 1 |
| Cataneo, EA; Leiguarda, R; Manes, F; Merello, M; Petracca, G; Starkstein, S | 1 |
| Boldry, RC; Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Kraus, PH | 1 |
| Araya, F; Castillo, JL; Miranda, CM; Sáez, D | 1 |
| Baĭchurina, AZ; Garaev, RS; Semina, II | 1 |
| Cicardi, MC; Loberti, M; Peppe, A; Pierantozzi, M; Semprini, R; Stanzione, P; Traversa, R | 1 |
| Marsden, CD; Nordera, G; Stocchi, F | 1 |
| Cammarota, A; Leiguarda, R; Merello, M; Pikielny, R | 1 |
| Flumerfelt, BA; Newman, DD; Rajakumar, N; Stoessl, AJ | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Esteban Muñoz, J; Marín, C; Martí, MJ; Tolosa, E | 1 |
| Bonuccelli, U; Napolitano, A; Rossi, B | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S | 1 |
| Sugiura, K; Yokoyama, M; Yoshimura, H | 1 |
| Barlas, C; Chugh, A; Johnson, RL; Marcotte, ER; Mishra, RK; Whan, D | 1 |
| Arnold, G; Gasser, T; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Austin, S; Crameri, J; Hughes, AJ; Hunter, PC; Woodward, MC | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Bassi, A; Bernardi, G; Mazzone, P; Stanzione, P; Stefani, A; Vangelista, T | 1 |
| Arnold, G; Gasser, T; Künig, G; Oertel, WH; Pogarell, O; Schwarz, J; Tatsch, K | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Koudsie, A; Krack, P; Le Bas, JF; Limousin, P; Pollak, P | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| el-Kadi, AO; Sharif, SI | 1 |
| Agid, Y; Dziewczapolski, G; García, MC; Gershanik, O; Menalled, LB; Murer, MG; Raisman-Vozari, R | 1 |
| Cohen, LK; Leff, SE; Mandel, RJ; Rendahl, KG; Snyder, RO; Spratt, SK | 1 |
| Colzi, A; Lees, AJ; Turner, K | 1 |
| Kang, UJ; Leff, SE; Mandel, RJ; Rendahl, KG; Spratt, SK | 1 |
| Allikmets, L; Matto, V; Skrebuhhova, T | 1 |
| Honey, CR; Shen, H | 1 |
| Guerra, MJ; Labandeira-García, JL; López-Martín, E; Rozas, G | 1 |
| Palmiter, RD; Szczypka, MS; Zhou, QY | 1 |
| Ekesbo, A; Låengström, B; Rydin, E; Sydow, O; Tedroff, J; Torstenson, R | 1 |
| McAuley, J; Shahmanesh, M; Swash, M | 1 |
| Agid, Y; Debilly, B; Durif, F; Vidailhet, M | 1 |
| Albanese, A; Moro, E | 1 |
| Möller, JC; Oertel, WH; Pogarell, O | 1 |
| Kannari, K; Maeda, T; Matsunaga, M; Suda, T; Tanaka, H; Tomiyama, M | 1 |
| Albanese, A; LeWitt, PA | 1 |
| Ellis, CM; Ray Chaudhuri, K; Reuter, I | 1 |
| Neef, C; van Laar, T | 1 |
| Asmakova, LS; Bondarenko, NA; Gudasheva, TA; Kalinina, TS; Ostrovskaya, RU; Seredenin, SB; Voronina, TA; Zaitseva, NI | 1 |
| Sourkes, TL | 1 |
| Carter, JH; Nutt, JG | 1 |
| Mandel, RJ | 1 |
| Albanese, A; Colosimo, C; Moro, E; Rossi, P; Tonali, P | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Stoessl, AJ; Van Kampen, JM | 1 |
| McGeer, EG; Stoessl, AJ; Van Kampen, JM | 1 |
| Sit, SY | 1 |
| Kuritzky, A; Melamed, E; Merims, D; Ziv, I; Zoldan, J | 1 |
| Jenner, P; Smith, LA; Treseder, SA | 1 |
| Bhatia, KP; Münchau, A | 1 |
| Clarke, CE; Davies, P | 1 |
| Bergmann, R; Gasparini, F; Kuhn, R; Spooren, WP | 1 |
| Abe, K; Kashihara, K; Manabe, Y; Shiro, Y; Warita, H | 1 |
| Koga, K; Kurokawa, M; Kuwana, Y; Nakamura, J; Ochi, M | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| de Luis, P; del Real, MA; Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Albanese, A; Bonuccelli, U; Brefel, C; Chaudhuri, KR; Colosimo, C; Eichhorn, T; Melamed, E; Pollak, P; Van Laar, T; Zappia, M | 1 |
| Ingvarsson, PE; Johnels, B; Olsson, T; Steg, G | 1 |
| Boryczka, AT; Ganong, WF; Grumbach, M; Holland, J; Kaplan, S; Lovinger, R; Reid, IA; Salmon, J; Shackelford, R | 1 |
| Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Peggs, D | 1 |
| Barbato, L; De Pandis, MF; Ruggieri, S; Stocchi, F; Vacca, L; Valente, M | 1 |
| Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R | 1 |
| Charles, KJ; Gray, J; Hunter, AJ; Jenner, P; Medhurst, AD; Reavill, C; Shale, JA; Zeng, BY | 1 |
| Bareš, M; Hortová, H; Kanovský, P; Kubová, D; Rektor, I; Streitová, H; Znojil, V | 1 |
| Abe, K; Kashihara, K; Manabe, Y; Murakami, T | 1 |
| Metz, GA; Whishaw, IQ | 1 |
| Barone, P; Cicarelli, G; De Michele, G; Pellecchia, MT; Pizzolato, G | 1 |
| Ghika, J; Solida, A; Vingerhoets, F | 1 |
| Lees, AJ; Manson, AJ; Turner, K | 1 |
| Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Aniello, MS; De Mari, M; Defazio, G; Lamberti, P; Zenzola, A | 1 |
| Albani, G; Astolfi, V; Baudo, S; Bergamasco, B; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Lopiano, L; Mauro, A; Priano, L; Rizzone, M | 1 |
| Bonuccelli, U; Caltagirone, C; Carlesimo, GA; Costa, A; Dell'Agnello, G; Murri, L; Peppe, A | 1 |
| Archer, T; Fredriksson, A | 1 |
| Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Benz, S; Börnke, C; Müller, T; Przuntek, H; Russ, H | 1 |
| Gilgun-Sherki, Y; Melamed, E; Offen, D; Ziv, I | 1 |
| Gilgun-Sherki, Y; Mechoulam, R; Melamed, E; Offen, D | 1 |
| Stocchi, F | 2 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Ceballos-Baumann, A | 1 |
| Antonini, A; Basile, G; Di Blasi, L; Di Raimondo, G; Di Rosa, AE; Epifanio, A; Imbesi, D; La Spina, P; Martino, G; Morgante, L; Stocchi, F; Tetto, A | 1 |
| Albani, G; Bergamasco, B; Brioschi, A; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Guastamacchia, G; Lopiano, L; Mauro, A; Priano, L; Rizzone, M | 1 |
| Bergman, J; Eskola, O; Forsback, S; Grönroos, T; Haapalinna, A; Haaparanta, M; Marjamäki, P; Niemi, R; Rinne, J; Solin, O | 1 |
| Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA | 1 |
| Kang, UJ; Kim, YS; Lee, EA; Lee, WY | 1 |
| Hanger, D; Joyce, JN; Reploge, M; Yarkov, AV | 1 |
| Antonini, A; Berto, P; D'Ausilio, A; Marconi, S; Tamma, F; Valzania, F | 1 |
| Swope, DM | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Tanaka, H; Tomiyama, M | 1 |
| De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U | 1 |
| Sobolewski, P | 1 |
| Leenders, KL; Linazasoro, G | 1 |
| Albani, G; Bergamasco, B; Brioschi, A; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Lopiano, L; Mauro, A; Priano, L; Rizzone, M; Scaglione, F | 1 |
| Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV | 1 |
| Debilly, B; Durif, F; Lees, AJ; Rascol, O; Zijlmans, JC | 1 |
| Bianchi, AM; Foffani, G; Locatelli, M; Moxon, KA; Pellegrini, M; Pesenti, A; Priori, A; Tamma, F; Villani, RM | 1 |
| Bhatia, K; Evans, A; Hoffman, M; Hughes, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Quinn, N; Swinn, L; Watt, H | 1 |
| Happe, S; Helmschmied, K; Neubert, K; Paulus, W; Tings, T; Trenkwalder, C; Wuttke, W | 1 |
| Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Comella, C; Widnell, KL | 1 |
| Onofrj, M; Thomas, A | 1 |
| Glavan, G; Zivin, M | 1 |
| Hedrich, K; Kann, M; Kis, B; Klein, C; Kömpf, D; Pramstaller, PP; Schwinger, E | 1 |
| Hnasko, TS; Kremer, EJ; Palmiter, RD; Robinson, S; Sotak, BN | 1 |
| Cauli, O; Morelli, M; Pinna, A | 1 |
| Bunney, BS; Shi, WX; Zhou, Y | 1 |
| Chen, JJ; Obering, C | 1 |
| Antonini, A; Bonetti, A; Cilia, R; De Gaspari, D; Landi, A; Mariani, CB; Morgante, L; Natuzzi, F; Pezzoli, G; Sganzerla, E; Siri, C | 1 |
| Karlsborg, M; Regeur, L | 1 |
| Bilbao, G; Garibi, J; Gómez-Urquijo, S; Linazasoro, G; Miguens, N; Ruiz-Ortega, JA; Ugedo, L; Ulibarri, I | 1 |
| Aniel-Quiroga, MA; Barcena, J; Cruz Lachén, M; Gómez, JC; Hurtado, P; Lezcano, E; Pérez Bas, M; Rouco, I; Velasco, F; Zarranz, JJ | 1 |
| Borman, JB; Houminer, E; Khaliulin, I; Schneider, A; Schwalb, H | 1 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; Manrique, M; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M; Zamarbide, I | 1 |
| Asmus, F; Bötzel, K; Deutschländer, A; Gasser, T; Klopstock, T; Marelli, E | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V | 1 |
| Köllensperger, M; Poewe, W; Reindl, M; Stefanova, N; Wenning, GK | 1 |
| Ludin, HP; Surber, Ch | 1 |
| Castaño, B; Giménez-Roldán, S; Mateo, D | 1 |
| Bachmann, CG; Happe, S; Helmschmied, K; Neubert, K; Paulus, W; Trenkwalder, C; Wuttke, W | 1 |
| Boesch, S; Ceballos-Baumann, A; Dressler, D; Eggert, K; Gasser, T; Honig, H; Müller, T; Odin, P; Poewe, W; Reichmann, H; Sieb, JP; Storch, A; Trenkwalder, C | 1 |
| Abuirmeileh, A; Biggs, CS; Harkavyi, A; Kingsbury, AE; Lever, R; Whitton, PS | 1 |
| Glavan, G | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Nyholm, D | 1 |
| Dechant, G; Hainzer, M; Köllensperger, M; Nikkhah, G; Pallua, A; Poewe, W; Puschban, Z; Reindl, M; Stefanova, N; Wenning, GK | 1 |
| Aguilar, E; Bartoszyk, GD; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Poewe, W | 1 |
| Ding-Fang, C; Guo-Hua, W; Hong-Min, T; Hua-Wei, L; Jun, M; Jun-Peng, G; Shan, S; Wen-Wei, L; Xiang-Yu, W; Ya-Ling, H; Yan-Hong, T; Yi, F; Yue, F; Yun-Ke, Y | 1 |
| Antonini, A; Tolosa, E | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A; Tronci, E | 1 |
| Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL | 1 |
| Beal, MF; Bogdanov, M; Burke, RE; Geghman, K; Jackson-Lewis, V; Li, C; Li, Y; Liu, W; Oo, TF; Przedborski, S; Tang, Y; Wang, L; Zhou, C | 1 |
| Clarke, CE; Grosset, D; Stewart, D; Worth, P | 1 |
| Reichmann, H | 1 |
| Antonini, A; Odin, P | 1 |
| Deuschl, G | 1 |
| San Luciano, M; Saunders-Pullman, R | 1 |
| Kirik, D; Sahin, G; Ulusoy, A | 1 |
| Jugel, C; Klostermann, F; Marzinzik, F | 1 |
| Hakimi, R | 1 |
| Brantley, E; Karain, B; Shi, WX; Xu, D | 1 |
| Af Bjerkén, S; Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Albanese, A; Dollenz, C; Elia, AE; Soliveri, P | 1 |
| Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C | 1 |
| Dunnett, SB; Heuer, A; Lane, EL; Smith, GA | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Schnitzler, A; Südmeyer, M; Wojtecki, L | 1 |
| Fernandez, HH | 1 |
| Ferrara, JM; Hunter, C; Mostile, G; Ondo, WG | 1 |
| Burkhard, PR; Vingerhoets, FJ | 1 |
| Belavic, J | 1 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; López-Azcárate, J; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Burguera, JA; Martínez-Castrillo, JC | 1 |
| Grandas, FJ; Sesar-Ignacio, Á | 1 |
| García-Ruiz, PJ; Luquin, MR | 1 |
| Chacón, JR; Mata, M | 1 |
| Albanese, A; Antonini, A; Chaudhuri, KR; Clarke, CE; de Bie, RM; Deuschl, G; Eggert, K; Houeto, JL; Kulisevsky, J; Nyholm, D; Odin, P; Oertel, W; Poewe, W; Pollak, P; Rabey, JM; Rascol, O; Ruzicka, E; Samuel, M; Speelman, H; Sydow, O; Valldeoriola, F; van der Linden, C; Volkmann, J; Østergaard, K | 1 |
| Kanda, T; Miyauchi, N; Yamada, K | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Worth, PF | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Higashi, Y; Miyazaki, I; Namba, M; Ogawa, N | 1 |
| Aschermann, Z; Komoly, S; Kovács, N | 1 |
| Trenkwalder, C | 1 |
| Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A | 1 |
| Katunina, EA; Titova, NV | 1 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Odin, P; Walter, E | 1 |
| Antonini, A; Bryndum, N; Calandrella, D; Chaudhuri, KR; Dafsari, HS; Ebersbach, G; Glad, A; Henriksen, T; Katzenschlager, R; Kramberger, MG; Martin, A; Martinez-Martin, P; Odin, P; Palhagen, S; Pirtosek, Z; Reddy, P; Reichmann, H; Rizos, A; Samuel, M; Storch, A; Svenningsson, P; Timmermann, L; Todorova, A; Tomantschger, V; Trost, M; Volkmann, J; Wenzel, K | 1 |
| Jeon, SR; Kim, YH; Shin, ES; Yoon, HH | 1 |
| Nutt, JG | 1 |
| Duan, SJ; Han, B; Lu, Y; Wang, LJ; Wang, SY; Wang, T; Zhu, Q | 1 |
| Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| Czarnecka, A; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
| Kokare, DM; Shelkar, GP; Subhedar, NK; Upadhya, MA | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Atula, S; Autere, J; Eerola-Rautio, J; Kaasinen, V; Kauppinen, M; Martikainen, K; Pekkonen, E; Ruottinen, H; Viljamaa, M | 1 |
| Bez, F; Cenci, MA; Francardo, V | 1 |
| Agro, A; Bilbault, T; Dubow, J; Dzyngel, B; Hauser, RA; Isaacson, S; Olanow, CW; Shill, H | 1 |
| Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J | 1 |
| Garcia-Agua Soler, N; Garcia-Ruiz, AJ; Vivancos-Matellano, F | 1 |
| Borgemeester, R; van Laar, T | 1 |
| Djamshidian, A; Poewe, W | 1 |
| Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR | 1 |
| Funamizu, Y; Mizukami, H; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yagihashi, S | 1 |
| Alam, M; Grothe, C; Jin, X; Krauss, JK; Ratzka, A; Rumpel, R; Schwabe, K; Tschirner, SK; von Wrangel, C | 1 |
| Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB | 1 |
| Mundt-Petersen, U; Odin, P | 1 |
| Altschüler, J; Beck, MH; Haumesser, JK; Kühn, AA; Kühn, J; Nikulin, VV; van Riesen, C | 1 |
| Barbiani, D; Benedetti, F; Carlino, E; Dematteis, F; Frisaldi, E; Lanotte, M; Lopiano, L; Zibetti, M | 1 |
| Ai, Y; Andersen, AH; Evans, A; Forman, E; Gash, DM; Grondin, R; Hardy, PA; Yue, G; Yue, J; Zhang, R; Zhang, Z | 1 |
| Ando, K; Inoue, R; Kawai, K; Nishime, C; Nishinaka, E; Tsutsumi, H; Urano, K | 1 |
| Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A | 1 |
| Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L | 1 |
| Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J | 1 |
| Antonini, A; Nitu, B | 1 |
| Antonini, A; Jost, WH | 1 |
| Drapier, D; Drapier, S; Duprez, J; Houvenaghel, JF; Riou, A; Robert, GH; Sauleau, P; Vérin, M | 1 |
| Fernandez, HH; Hengartner, D | 1 |
| Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG | 1 |
| Antonini, A; Ashkan, K; Barbe, MT; Borgemeester, RWK; Dafsari, HS; Dos Santos Ghilardi, MG; Ebersbach, G; Evans, J; Fink, GR; Fonoff, ET; Henriksen, T; Kramberger, M; Martinez-Martin, P; Odin, P; Petry-Schmelzer, JN; Pirtošek, Z; Ray Chaudhuri, K; Reddy, P; Rizos, A; Sauerbier, A; Silverdale, M; Timmermann, L; Trost, M; Visser-Vandewalle, V | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L | 1 |
| Bhargava, P; Blum, D; Espay, AJ; Factor, SA; Hauser, RA; Isaacson, S; Leinonen, M; Navia, B; Olanow, CW; Pahwa, R; Sciarappa, K; Shill, HA | 1 |
| Do, JH; Pepe, D | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| Anheim, M; Grillon, A; Lipsker, D; Moegle, C; Velter, C | 1 |
| Shao, M; Wang, R | 1 |
| Baumann, CR; Oertel, MF; Stieglitz, LH | 1 |
| Bergquist, F; Dizdar, N; Hagell, P; Hellqvist, C; Höglund, A; Johansson, A; Johansson, EL; Karlberg, C; Löwed, B; Lundgren, M; Rådberg, J; Sjöström, AC; Willows, T | 1 |
| Müller, T | 1 |
| de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R | 1 |
| Caughman, CY; Factor, S | 1 |
| Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N | 1 |
| Calvano, A; Chaudhuri, KR; Martinez-Martin, P; Odin, P; Pietrzykowski, T; Rodriguez-Blazquez, C; Smilowska, K; van Wamelen, DJ | 1 |
| Bologna, M; Colosimo, C; Marsili, L; Miyasaki, JM | 1 |
| Paton, DM | 1 |
| Bloem, BR; de Bie, RMA; Esselink, R; Groenewoud, H; Meinders, MJ; Nijhuis, FAP; Post, B | 1 |
| Comella, CL; Hauser, RA; LeWitt, PA | 1 |
| Olanow, CW; Poewe, W; Rascol, O; Stocchi, F | 1 |
| Anan, C; Bhidayasiri, R; Chaudhuri, KR; Phimpha, A; Phokaewvarangkul, O; van Laar, T | 1 |
| Larson, D; Simuni, T | 1 |
| Gaburo, K; Kirson, N; Mehta, D; Pappert, E; Thach, A; Williams, GR; Yang, K; Zichlin, ML | 1 |
| Fernandez, HH; Mata, IF; Salles, PA | 1 |
| Fernandez, HH; Liao, J; Mata, IF; Salles, PA; Shuaib, U | 1 |
| Boura, I; Chaudhuri, KR; Espay, AJ; Jenner, P; Leta, V; Odin, P; Rota, S; Urso, D; van Wamelen, DJ | 1 |
| Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Isaacson, SH; Kandukuri, PL; Merola, A; Odin, P; Pahwa, R; Parra, JC; Wang, L; Yan, CH; Zadikoff, C | 1 |
| Hallett, M; Katzenschlager, R; Pirker, W; Poewe, W | 1 |
| Bouillot, R; Delabrousse-Mayoux, JP; Leblanc, A; Patat, M; Pouyet, A; Sogni, L; Vérin, M; Viakhireva-Dovganyuk, I; Zagnoli, F; Ziegler, M | 1 |
| LeWitt, PA; Martinez-Nunez, AE | 1 |
| Auffret, M; Bhidayasiri, R; Borovečki, F; Falup-Pecurariu, C; Jenner, P; Jost, WH; Leta, V; Verin, M; Weiss, D | 1 |
| Arif, C; Koneru, V; Ondo, WG | 1 |
| Bhidayasiri, R; Henriksen, T; Katzenschlager, R; Lees, A; Lockhart, D; Staines, H | 1 |
| Batzu, L; Bhattacharya, K; Borgohain, R; Chaudhuri, KR; Dhamija, RK; Falup-Pecurariu, C; Goyal, V; Kumar, NSS; Kumar, S; L K, P; Metta, V; Mrudula, R; Rodriguez-Blazquez, C; S, A | 1 |
92 review(s) available for apomorphine and levodopa
| Article | Year |
|---|---|
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phosphodiesterase Inhibitors; Piribedil; Tremor | 1978 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Striatum; Dogs; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Hypothermia; Levodopa; Memory; Mice; Opioid-Related Disorders; Parkinson Disease; Psychotic Disorders; Rats; Receptors, Dopamine; Sleep; Stereotyped Behavior; Substantia Nigra; Synapses; Synaptic Transmission | 1979 |
Dopaminergic mechanisms and stereotyped behaviour in birds.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Birds; Brain Chemistry; Corpus Striatum; Dopamine; Humans; Levodopa; Putamen; Receptors, Dopamine; Stereotyped Behavior; Thyrotropin-Releasing Hormone | 1979 |
[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
Topics: Animals; Apomorphine; Benzamides; Chorea; Fluorescent Antibody Technique; Guinea Pigs; Haloperidol; Humans; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1978 |
Dopaminergic agents and circling behaviour.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Cyclic AMP; Dopamine; Levodopa; Limbic System; Motor Activity; Norepinephrine; Receptors, Dopamine; Serotonin; Substantia Nigra | 1978 |
On the roles of dopamine and noradrenaline in animal behaviour.
Topics: Adrenergic alpha-Antagonists; Aggression; Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Body Temperature Regulation; Cats; Clonidine; Conditioning, Operant; Dopamine; Drinking Behavior; Enzyme Inhibitors; Feeding Behavior; Haplorhini; Humans; Levodopa; Motor Activity; Norepinephrine; Rage; Rats; Self Stimulation; Stereotyped Behavior; Stress, Psychological | 1975 |
Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease; Piribedil; Receptors, Dopamine | 1979 |
Compulsive gnawing.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Behavior, Animal; Benserazide; Dextroamphetamine; Dihydroxyphenylalanine; Dopamine; Iproniazid; Levodopa; Male; Methyldopa; Methyltyrosines; Rats; Serotonin; Structure-Activity Relationship; Time Factors | 1976 |
On the role of dopamine in the pathophysiology of anorexia nervosa.
Topics: 17-Ketosteroids; Amphetamine; Anorexia Nervosa; Apomorphine; Compulsive Personality Disorder; Dopamine; Female; Glucose Tolerance Test; Gonadotropins, Pituitary; Humans; Levodopa; Luteinizing Hormone; Male; Movement Disorders; Parkinson Disease; Schizophrenia; Steroids; Thinness | 1976 |
Turning in circles: the neuropharmacology of rotation.
Topics: Amphetamines; Animals; Apomorphine; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Functional Laterality; Levodopa; Methods; Models, Neurological; Motor Activity; Rotation; Sex Factors; Species Specificity; Substantia Nigra | 1976 |
Monoaminergic drugs: general pharmacology.
Topics: Absorption; Amantadine; Amphetamine; Animals; Apomorphine; Brain; Catecholamines; Cats; Cattle; Deamination; Decarboxylation; Dogs; Half-Life; Haplorhini; Humans; Hydroxylation; Kinetics; Levodopa; Methylation; Mice; Rats | 1976 |
Monkeys with nigrostriatal lesions effects of monoaminergic drugs.
Topics: Amino Acids; Animals; Antiparkinson Agents; Apomorphine; Biogenic Amines; Carboxy-Lyases; Catechol O-Methyltransferase Inhibitors; Chlorocebus aethiops; Corpus Striatum; Drug Interactions; Haplorhini; Harmaline; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Substantia Nigra; Tremor | 1976 |
Drugs that affect the breast and lactation.
Topics: Androgens; Apomorphine; Barbiturates; Breast; Breast Neoplasms; Bromocriptine; Contraceptives, Oral, Hormonal; Estrogens; Female; Galactorrhea; Humans; Lactation; Levodopa; Male; Monoamine Oxidase Inhibitors; Nandrolone; Phenothiazines; Pregnancy; Progesterone; Prolactin; Psychotropic Drugs; Pyridoxine; Steroids | 1975 |
Biological transmethylation involving S-adenosylmethionine: development of assay methods and implications for neuropsychiatry.
Topics: Acetylserotonin O-Methyltransferase; Animals; Apomorphine; Blood Platelets; Brain; Histamine; Humans; Leukemia; Levodopa; Methionine; Methionine Adenosyltransferase; Methyltransferases; Monoamine Oxidase Inhibitors; Pyrogallol; Rabbits; Rats; S-Adenosylmethionine; Schizophrenia; Serotonin; Tetrahydrofolates | 1975 |
Motor response to repeated dopaminergic stimulation in Parkinson's disease.
Topics: Animals; Apomorphine; Dopamine Agents; Haplorhini; Humans; Levodopa; Movement; Parkinson Disease | 1992 |
[Current therapeutic approach in Parkinson disease].
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E | 1992 |
[Use of apomorphine in the treatment of Parkinson's disease].
Topics: Apomorphine; Domperidone; Drug Combinations; Humans; Infusions, Intravenous; Injections, Subcutaneous; Levodopa; Parkinson Disease | 1991 |
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
Topics: Administration, Oral; Aged; Apomorphine; Drug Evaluation; False Negative Reactions; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease, Secondary; Probability | 1990 |
The modern management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Selegiline | 1990 |
The controversial role of bromocriptine in Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease; Time Factors | 1985 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Cardiac; Carbidopa; Depression, Chemical; Diet; Disulfiram; Drug Interactions; Drug Therapy, Combination; Endocrine Glands; Glaucoma; Humans; Hydrogen-Ion Concentration; Levodopa; Mice; Parasympatholytics; Parkinson Disease; Stomach | 1974 |
[Myoclonus induced by some benzodiazepines in the Papio papio. Comparison with myoclonus induced by intermittent light stimulation (author's transl)].
Topics: Allylglycine; Animals; Anti-Anxiety Agents; Apomorphine; Diazepam; Levodopa; Lorazepam; Myoclonus; Papio; Photic Stimulation; Serotonin; Valproic Acid | 1982 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
[New directions in contemporary pharmacotherapy of parkinsonism (review)].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Lisuride; Oxprenolol; Parkinson Disease; Piracetam; Piribedil; Propranolol | 1984 |
On the mechanism of the antiparkinsonian action of 1-DOPA and bromocriptine: a theoretical and experimental analysis of dopamine receptor sub- and supersensitivity.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Bromocriptine; Humans; Hydroxydopamines; Levodopa; Receptors, Dopamine | 1980 |
Apomorphine for motor fluctuations and freezing in Parkinson's disease.
Topics: Administration, Intranasal; Administration, Rectal; Administration, Sublingual; Apomorphine; Clinical Trials as Topic; Half-Life; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
New directions in the drug treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Early diagnosis in Parkinson's disease--limitation of biochemical markers and instrumental methods.
Topics: Apomorphine; Biomarkers; Cell Death; Corpus Striatum; Diagnostic Imaging; Electrophysiology; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Substantia Nigra; Time Factors | 1996 |
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
Topics: Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Globus Pallidus; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Sleep Wake Disorders; Stereotaxic Techniques; Thalamus | 1997 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
Apomorphine and levodopa challenge in patients with a focal midbrain lesion.
Topics: Adult; Antiparkinson Agents; Apomorphine; Brain Damage, Chronic; Female; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
[The diagnosis of the parkinsonian syndrome].
Topics: Antiparkinson Agents; Apomorphine; Brain; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease, Secondary; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1999 |
New delivery systems for antiparkinsonian drugs.
Topics: Administration, Cutaneous; Antiparkinson Agents; Apomorphine; Delayed-Action Preparations; Drug Delivery Systems; Humans; Levodopa; Lisuride | 1999 |
Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Parkinson Disease; Time Factors | 1999 |
"Rational hope" in the early treatment of Parkinson's disease.
Topics: Apomorphine; Aporphines; Harmine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease | 1999 |
Dopamine agonists in the treatment of Parkinson s disease past, present and future.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease; Structure-Activity Relationship | 2000 |
Pharmacological treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease.
Topics: Apomorphine; Diagnostic Tests, Routine; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity | 2000 |
DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Psychomotor Disorders; Randomized Controlled Trials as Topic | 2002 |
Prevention and treatment of motor fluctuations.
Topics: Antiparkinson Agents; Apomorphine; Benzophenones; Dyskinesias; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Rapid treatment of "wearing off" in Parkinson's disease.
Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease; Salvage Therapy; Time Factors | 2004 |
[Treatment of Parkinson disease in patients with surgical problems].
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Health Status; Humans; Levodopa; Parkinson Disease; Postoperative Period | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Economics, Pharmaceutical; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease | 2005 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
Treatments for Parkinson disease--past achievements and current clinical needs.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic alpha-Antagonists; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cholinesterase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Excitatory Amino Acid Antagonists; History, 20th Century; Humans; Levodopa; Parkinson Disease; Serotonin Agents | 2009 |
Use of apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dopamine Agonists; Humans; Levodopa; Lisuride; Parkinson Disease | 2008 |
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
Topics: Anticonvulsants; Apomorphine; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Patient Selection; Risk Assessment; Risk Factors | 2009 |
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2009 |
[Diagnosis and therapy of idiopathic Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Deep Brain Stimulation; Diagnosis, Differential; Dopamine Agonists; Humans; Indans; Levodopa; Mental Status Schedule; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2006 |
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.
Topics: Animals; Apomorphine; Drug Delivery Systems; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2009 |
[Parkinson's disease - the future of invasive therapy].
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Genetic Therapy; Humans; Levodopa; Parkinson Disease; Stem Cell Transplantation | 2010 |
Substance abuse and movement disorders.
Topics: Alcoholism; Animals; Apomorphine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Substance Withdrawal Syndrome; Substance-Related Disorders | 2009 |
[Therapy options in the case of advanced therapy resistant Morbus Parkinson].
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Cross-Sectional Studies; Deep Brain Stimulation; Drug Resistance; Humans; Infusion Pumps, Implantable; Levodopa; Neurologic Examination; Parkinson Disease; Population Dynamics | 2010 |
[Current treatment strategies for Parkinson's disease].
Topics: Aged; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Critical Care; Deep Brain Stimulation; Dementia; Depression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Europe; Female; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Psychotic Disorders; Sleep Wake Disorders; Tremor | 2011 |
Updates in the medical management of Parkinson disease.
Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergic Antagonists; Disease Progression; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease | 2012 |
[Resistance to treatment in movement disorders].
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Drug Resistance; Essential Tremor; Humans; Levodopa; Movement Disorders; Neurosurgery; Parkinson Disease; Treatment Failure | 2012 |
[Proposed alternative to standard apomorphine challenge test].
Topics: Antidotes; Antiparkinson Agents; Apomorphine; Carbidopa; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Levodopa; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors | 2012 |
[Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Topics: Aftercare; Ambulatory Care; Antiparkinson Agents; Apomorphine; Benserazide; Carbidopa; Caregivers; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Patient Education as Topic; Patient Selection; Retrospective Studies | 2012 |
[Limits of conventional oral and transdermal medication in Parkinson's disease].
Topics: Administration, Cutaneous; Administration, Oral; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Indans; Injections, Subcutaneous; Levodopa; Meta-Analysis as Topic; Multicenter Studies as Topic; Parkinson Disease | 2012 |
[Candidate patient for subcutaneous apomorphine injection].
Topics: Abnormalities, Drug-Induced; Antiparkinson Agents; Apomorphine; Contraindications; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypotension, Orthostatic; Injections, Subcutaneous; Lactation; Levodopa; Parkinson Disease; Patient Selection; Pregnancy; Pregnancy Complications; Psychoses, Substance-Induced | 2012 |
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Administration Routes; Evidence-Based Practice; Humans; Levodopa; Parkinson Disease | 2013 |
[Subcutaneous apomorphine injection: rescue management of motor fluctuations associated with levodopa-therapy].
Topics: Animals; Antiparkinson Agents; Apomorphine; Circadian Rhythm; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Receptors, Dopamine; Salvage Therapy; Self Administration | 2013 |
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection | 2013 |
[Treatment possibilities in advanced Parkinson's disease].
Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2013 |
[The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2013 |
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2016 |
Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
Topics: Animals; Antiparkinson Agents; Apomorphine; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease | 2016 |
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2017 |
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2017 |
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2018 |
[Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Duodenum; Humans; Infusions, Intravenous; Infusions, Parenteral; Jejunum; Levodopa; Movement Disorders; Parkinson Disease | 2018 |
The next chapter in symptomatic Parkinson disease treatments.
Topics: Apomorphine; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2019 |
Apomorphine in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Dopamine Agonists; Humans; Injection Site Reaction; Injections, Subcutaneous; Levodopa; Parkinson Disease; Subcutaneous Tissue | 2020 |
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2020 |
A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2021 |
Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
Topics: Antiparkinson Agents; Apomorphine; Cost-Benefit Analysis; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
Topics: Activities of Daily Living; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Topics: Antiparkinson Agents; Apathy; Apomorphine; Humans; Levodopa; Parkinson Disease | 2021 |
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease | 2022 |
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Aged; Apomorphine; Carbidopa; Humans; Levodopa; Middle Aged; Network Meta-Analysis; Parkinson Disease; Quality of Life | 2022 |
Pharmacological Treatment of Tremor in Parkinson's Disease Revisited.
Topics: Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tremor | 2023 |
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2023 |
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
52 trial(s) available for apomorphine and levodopa
| Article | Year |
|---|---|
Studies on the anti-dyskinesia effect of apomorphine in man.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Clinical Trials as Topic; Drug Evaluation; Female; Haloperidol; Humans; Huntington Disease; Injections, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders | 1976 |
Impaired responses of growth hormone and blood eosinophils to L-dopa in atopy.
Topics: Apomorphine; Asthma; Blood Cell Count; Clinical Trials as Topic; Eosinophils; Female; Growth Hormone; Humans; Levodopa; Male; Placebos; Rhinitis, Allergic, Seasonal | 1977 |
Effects of apomorphine and apomorphine-L-dopa-carbidopa on alcohol post-intoxication symptoms.
Topics: Adult; Aged; Alcoholic Intoxication; Alcoholism; Apomorphine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged | 1978 |
Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
Topics: Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Alleviation of manic symptoms with catecholamine agonists.
Topics: Apomorphine; Bipolar Disorder; Clinical Trials as Topic; Dextroamphetamine; Double-Blind Method; Humans; Levodopa; Male; Methylphenidate; Middle Aged | 1979 |
Catecholaminergic drugs in chronic schizophrenia.
Topics: Adult; Apomorphine; Carbidopa; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Follicle Stimulating Hormone; Growth Hormone; Humans; Hydrazines; Imipramine; Levodopa; Luteinizing Hormone; Male; Middle Aged; Placebos; Schizophrenia, Disorganized; Testosterone | 1979 |
Meige disease: striatal dopaminergic preponderance.
Topics: Aged; Apomorphine; Basal Ganglia; Blepharospasm; Clinical Trials as Topic; Diagnosis, Differential; Eyelid Diseases; Facial Muscles; Female; Haloperidol; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Physostigmine; Placebos | 1979 |
[Polygraphic recording of tremor and of hypertonic phenomena. Application to the action of various drugs].
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopa Decarboxylase; Drug Combinations; Drug Evaluation; Electrodiagnosis; Electromyography; Humans; Levodopa; Medical Records; Muscle Tonus; Oscillometry; Parkinson Disease; Piribedil; Tremor | 1975 |
Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.
Topics: Administration, Oral; Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Growth Hormone; Humans; Kidney; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Secretory Rate | 1976 |
Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.
Topics: Adult; Apomorphine; Benztropine; Blood Glucose; Growth Hormone; Humans; Hydrocortisone; Levodopa; Male; Nausea; Placebos; Radioimmunoassay | 1975 |
Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine.
Topics: Adult; Apomorphine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Single-Blind Method | 1992 |
Sublingual apomorphine solution in Parkinson's disease.
Topics: Administration, Oral; Administration, Sublingual; Apomorphine; Domperidone; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Single-Blind Method | 1991 |
[Apomorphine in Parkinson disease].
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Blood pressure effects of apomorphine and domperidone in parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Blood Pressure; Clinical Trials as Topic; Domperidone; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Shy-Drager Syndrome | 1987 |
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
Topics: Acute Disease; Adult; Age Factors; Apomorphine; Carbidopa; Depression, Chemical; Dopamine; Humans; Levodopa; Male; Prolactin; Research Design; Schizophrenia; Schizophrenic Psychology; Sodium Chloride | 1985 |
Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects.
Topics: Adult; Apomorphine; Benztropine; Bromocriptine; Cholinergic Fibers; Dopamine; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Penis | 1984 |
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
Topics: Aged; Antiparkinson Agents; Apomorphine; Biological Availability; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Exercise Test; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Suppositories; Treatment Outcome | 1995 |
A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1993 |
Apomorphine and lisuride infusion. A comparative chronic study.
Topics: Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Lisuride; Long-Term Care; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease | 1993 |
Apomorphine test for dopaminergic responsiveness: a dose assessment study.
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine | 1993 |
[Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dopamine Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Topics: Administration, Intranasal; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Carbidopa; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1996 |
Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics.
Topics: Antiparkinson Agents; Apomorphine; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1995 |
Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease; Psychomotor Performance | 1996 |
A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Blood Pressure; Dopamine; Epinephrine; Female; Heart Rate; Human Growth Hormone; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Peripheral Nervous System; Prolactin; Sensitivity and Specificity | 1996 |
Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Cross-Over Studies; Double-Blind Method; Female; Humans; Levodopa; Motor Activity; Parkinson Disease, Secondary; Psychiatric Status Rating Scales; Schizophrenia | 1996 |
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Topics: Adult; Aged; Apomorphine; Atrophy; Benzamides; Binding Sites; Cerebral Cortex; Dopamine; Dopamine Agonists; Dopamine Antagonists; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Predictive Value of Tests; Putamen; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1997 |
123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Chi-Square Distribution; Disease Progression; Dopamine Agonists; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1998 |
Opposite motor effects of pallidal stimulation in Parkinson's disease.
Topics: Apomorphine; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 1998 |
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Topics: Administration, Intranasal; Aerosols; Aged; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Premedication; Treatment Outcome | 1998 |
Apomorphine and levodopa challenge in patients with a focal midbrain lesion.
Topics: Adult; Antiparkinson Agents; Apomorphine; Brain Damage, Chronic; Female; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease; Restless Legs Syndrome; Sleep Wake Disorders | 1999 |
Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors; Treatment Outcome | 2000 |
Acute challenge with apomorphine and levodopa in Parkinsonism.
Topics: Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Sensitivity and Specificity | 2000 |
[Apomorphine for treatment of "off-periods" in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Domperidone; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1999 |
The Posturo-Locomotion-Manual Test. A simple method for the characterization of neurological movement disturbances.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Diagnosis, Differential; Diagnostic Techniques, Neurological; Humans; Indoles; Levodopa; Locomotion; Middle Aged; Parkinson Disease; Posture | 2001 |
Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
Topics: Aged; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Time Factors; Treatment Outcome | 2001 |
Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 2002 |
Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Double-Blind Method; Drug Administration Routes; Drug Tolerance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2003 |
Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Area Under Curve; Drug Therapy, Combination; Emulsions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 2004 |
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Topics: Antiparkinson Agents; Apomorphine; Catechols; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease | 2004 |
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesias; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Prospective Studies; Self-Assessment; Statistics, Nonparametric | 2005 |
Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Disability Evaluation; Dopamine; Dopamine Agonists; Drug Administration Schedule; Female; Human Growth Hormone; Humans; Hydrocortisone; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2004 |
[Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Topics: Aged; Ambulatory Care; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outpatient Clinics, Hospital; Parkinson Disease; Prospective Studies; Subcutaneous Tissue; Telephone | 2007 |
Growth hormone response to low-dose apomorphine in restless legs syndrome.
Topics: Adult; Aged; Apomorphine; Dopamine Agonists; Female; Growth Hormone; Humans; Hydrocortisone; Levodopa; Male; Middle Aged; Restless Legs Syndrome | 2007 |
Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Topics: Administration, Oral; Aged; Apomorphine; Cross-Over Studies; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2009 |
Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dyskinesias; Female; Humans; Hypodermoclysis; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 2012 |
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Humans; Infusions, Subcutaneous; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Topics: Administration, Sublingual; Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Proof of Concept Study | 2016 |
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Topics: Administration, Sublingual; Adult; Aged; Antiparkinson Agents; Apomorphine; Canada; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; United States | 2020 |
Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2023 |
537 other study(ies) available for apomorphine and levodopa
| Article | Year |
|---|---|
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
Topics: Analgesics; Animals; Aporphines; Dopamine; Humans; Male; Mice; Neural Pathways; Rats; Reaction Time; Stereotyped Behavior; Structure-Activity Relationship | 1976 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Body Temperature; Brain; Dopamine; Female; Humans; Levodopa; Mice; Motor Activity; MSH Release-Inhibiting Hormone; Rats; Receptors, Drug; Stereotyped Behavior; Time Factors | 1976 |
Regulation of adrenal tyrosine hydroxylase activity: neuronal versus local control studied with apomorphine.
Topics: Adrenal Glands; Animals; Apomorphine; Catecholamines; Cattle; Levodopa; Male; Mecamylamine; Methyltyrosines; Neurons; Rats; Splanchnic Nerves; Tyrosine 3-Monooxygenase | 1976 |
Central dopaminergic and serotoninergic systems in the regulation of adrenal tyrosine hydroxylase.
Topics: 5-Hydroxytryptophan; 5,6-Dihydroxytryptamine; Adrenal Glands; Animals; Apomorphine; Bromocriptine; Carbidopa; Clonidine; Dopamine; Drug Interactions; Haloperidol; Hydroxydopamines; Injections, Intraventricular; Kinetics; Levodopa; Male; Piribedil; Pituitary Gland; Rats; Serotonin; Serotonin Antagonists; Splanchnic Nerves; Tyrosine 3-Monooxygenase | 1977 |
Paradoxical response to dopamine agonists in tardive dyskinesia.
Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Apomorphine; Benztropine; Clozapine; Deanol; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Levodopa; Physostigmine; Receptors, Dopamine; Reserpine; Stimulation, Chemical; Thioridazine | 1977 |
[The Cools and van Rossum theory and the pharmacology of Huntington's chorea].
Topics: Animals; Apomorphine; Brain; Cats; Dopamine; Dopamine beta-Hydroxylase; Drug Therapy, Combination; Ergonovine; Huntington Disease; Levodopa; Rats; Sulpiride; Tyrosine 3-Monooxygenase | 1977 |
Modification of electroshock fighting by drugs known to interact with dopaminergic and noradrenergic neurons in normal and brain lesioned rats.
Topics: Aggression; Amantadine; Animals; Apomorphine; Brain; Ditiocarb; Dopamine; Electroshock; Humans; Imipramine; Levodopa; Male; Neurons; Norepinephrine; Rats; Reserpine | 1977 |
[Dopaminergic neurons in the hypothalamo-hypophyseal system (IV): endocrinologic aspects of endogenous euphorigens].
Topics: Analgesics, Opioid; Antipsychotic Agents; Apomorphine; Dopamine; Endorphins; Enkephalins; Ergolines; Hallucinogens; Humans; Hypothalamo-Hypophyseal System; Levodopa; Neurons; Pituitary Hormones, Anterior; Serotonin | 1977 |
[Effects of dopaminergic stimulating agents, caffeine and antipsychotic drugs on rotational behaviour in mice with unilateral striatal 6-hydroxydopamine lesions (author's transl)].
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain Diseases; Caffeine; Corpus Striatum; Hydroxydopamines; In Vitro Techniques; Levodopa; Male; Methamphetamine; Methods; Mice; Receptors, Dopamine; Rotation | 1978 |
Inhibitory effects of substantia nigra on impulse transmission from nociceptors.
Topics: Animals; Apomorphine; Aporphines; Cats; Electric Stimulation; Female; Levodopa; Male; Methysergide; Neural Inhibition; Nociceptors; Physical Stimulation; Serotonin; Substantia Nigra; Synaptic Transmission; Tetrabenazine | 1979 |
Biochemical and behavioural studies on the interference between catecholaminergic and serotonergic central systems.
Topics: Adrenergic alpha-Agonists; Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Dopamine; Exploratory Behavior; Levodopa; Male; Motor Activity; Rats; Serotonin; Tryptophan | 1978 |
Dopaminergic antagonism of L-5-hydroxytryptophan-induced myoclonic jumping behavior.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Dopamine Antagonists; Ergolines; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Motor Activity; Myoclonus; Receptors, Dopamine; Stereotyped Behavior; Tetrahydronaphthalenes | 1979 |
Is a dopaminergic system involved in thyrotropin releasing hormone induced hyperthermia and in its potentiation by amphetamine?
Topics: alpha-Methyltyrosine; Amphetamine; Animals; Apomorphine; Chlorpromazine; Dopamine; Dopamine Agents; Female; Fever; Haloperidol; Levodopa; Methyltyrosines; Mice; Neurotransmitter Agents; p-Chloroamphetamine; Pimozide; Thyrotropin-Releasing Hormone | 1979 |
Editorial: After dopa.
Topics: Apomorphine; Chemoreceptor Cells; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Stimulation, Chemical | 1976 |
The effect of lithium on amphetamine-induced locomotor stimulation.
Topics: Amphetamine; Animals; Apomorphine; Clonidine; Drug Interactions; Female; Levodopa; Lithium; Methyltyrosines; Mice; Motor Activity; Reserpine; Time Factors | 1978 |
Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Benserazide; Callitrichinae; Disease Models, Animal; Drug Therapy, Combination; Haloperidol; Haplorhini; Hydroxydopamines; Hypothalamus; Levodopa; Locus Coeruleus; Male; Torticollis | 1979 |
Behavioral evidence for supersensitivity after chronic bromocriptine administration.
Topics: Animals; Apomorphine; Behavior, Animal; Bromocriptine; Drug Tolerance; Female; Humans; Levodopa; Male; Methylphenidate; Mice; Mice, Inbred C57BL; Motor Activity; Receptors, Dopamine; Stereotyped Behavior | 1979 |
Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey.
Topics: Animals; Apomorphine; Behavior, Animal; Cerebral Cortex; Cognition; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Haplorhini; Levodopa; Macaca mulatta; Norepinephrine | 1979 |
Long-term L-dopa pretreatment of mice: central receptor subsensitivity or supersensitivity?
Topics: Animals; Apomorphine; Benserazide; Dextroamphetamine; Drug Interactions; Levodopa; Male; Mice; Mice, Inbred Strains; Motor Activity; Receptors, Adrenergic; Time Factors | 1979 |
Monoaminergic mechanisms of stimulation-produced analgesia.
Topics: 5-Hydroxytryptophan; Analgesia; Animals; Apomorphine; Brain; Cerebral Aqueduct; Disulfiram; Dopamine; Electric Stimulation; Fenclonine; Haloperidol; Levodopa; Male; Methyltyrosines; Norepinephrine; Pain; Pimozide; Rats; Reaction Time; Receptors, Drug; Serotonin; Tetrabenazine | 1975 |
A quantitative rotational model for studying serotonergic function in the rat.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Brain; Carboxy-Lyases; Corpus Striatum; Dextroamphetamine; Fenclonine; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Models, Neurological; Motor Activity; Rats; Rotation; Serotonin | 1977 |
Effects of levodopa and dopamine of plasma glucose concentration in mice.
Topics: Animals; Apomorphine; Benserazide; Blood Glucose; Carbidopa; Cyproheptadine; Dopamine; Fatty Acids, Nonesterified; Fenclonine; Haloperidol; Insulin; Levodopa; Liver Glycogen; Male; Methysergide; Mice; Nialamide; Pargyline; Pimozide; Time Factors | 1977 |
Dopaminergic control of adenohypophyseal growth after oestrogens: negative results with L-DOPA, RO-4-4602, alpha-methyl-DOPA, apomorphine, haloperidol, pyridoxine and cyproheptadine.
Topics: Animals; Apomorphine; Benserazide; Cyproheptadine; Estrogens; Haloperidol; Levodopa; Pituitary Gland, Anterior; Pyridoxine; Rats; Thyroxine-Binding Proteins | 1978 |
[Participation of monoaminergic mechanisms and the striatum in the development of "petit mal" induced by corazole].
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Amines; Chlorpromazine; Corpus Striatum; Drug Interactions; Electroencephalography; Epilepsy, Absence; Fenclonine; Haloperidol; Levodopa; Male; Pentylenetetrazole; Rats | 1978 |
Growth hormone and prolactin secretion in Huntington's disease.
Topics: Adult; Aged; Apomorphine; Chlorpromazine; Female; Growth Hormone; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Time Factors | 1979 |
Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington's chorea.
Topics: Adult; Apomorphine; Bromocriptine; Female; Growth Hormone; Humans; Huntington Disease; Hypothalamo-Hypophyseal System; Levodopa; Male; Middle Aged; Receptors, Dopamine | 1979 |
[Effect of catecholaminergic substances on the proconvulsive properties of the caudate nucleus].
Topics: Animals; Apomorphine; Behavior, Animal; Caudate Nucleus; Chlorpromazine; Disulfiram; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Electrodes, Implanted; Electroencephalography; Haloperidol; Levodopa; Male; Methyltyrosines; Neural Inhibition; Rats; Seizures; Sympathomimetics; Synaptic Transmission; Time Factors | 1975 |
Automatic registration of behaviour related to dopamine and noradrenaline transmission.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Dopamine; Dose-Response Relationship, Drug; Isotonic Solutions; Levodopa; Male; Methods; Motor Activity; Norepinephrine; Phenoxybenzamine; Rats; Synaptic Transmission | 1976 |
Effects of dopaminergic stimulants on cyclic nucleotide levels in mouse brain in vivo.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Benserazide; Brain; Cerebellum; Cyclic AMP; Cyclic GMP; Dopamine; Dose-Response Relationship, Drug; Humans; Isoquinolines; Levodopa; Male; Mice; Nucleotides, Cyclic; Stereotyped Behavior | 1976 |
Hypothesis: migraine, a central biochemical dysnociception.
Topics: Adult; Animals; Apomorphine; Circadian Rhythm; Dopamine; Female; Fever; Headache; Humans; Levodopa; Lysergic Acid Diethylamide; Male; Migraine Disorders; Nervous System; Norepinephrine; Pain; Perceptual Disorders; Phenylalanine; Psilocybin; Rats; Reserpine; Serotonin; Sleep; Somatosensory Cortex; Synaptic Transmission | 1976 |
Proposal of a new model with dopaminergic-cholinergic interactions for neuropharmacological investigations.
Topics: Acetylcholine; Animals; Apomorphine; Atropine; Benserazide; Bromocriptine; Central Nervous System; Dextroamphetamine; Dopamine; Extrapyramidal Tracts; Haloperidol; Levodopa; Models, Neurological; Motor Activity; Physostigmine; Piribedil; Planarians; Reserpine; Synaptic Transmission; Turbellaria | 1975 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines; Levodopa; Male; Naloxone; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Rats; Receptors, Opioid; Reserpine; Substantia Nigra | 1978 |
An analysis of behavioural effects produced by drug-induced changes of dopaminergic neurotransmission in the brain.
Topics: Amphetamines; Animals; Apomorphine; Behavior, Animal; Levodopa; Mice; Receptors, Dopamine; Synaptic Transmission | 1979 |
Experimental aggression and bruxism in rats.
Topics: Aggression; Animals; Apomorphine; Benserazide; Bruxism; Ditiocarb; Electroshock; Humans; Iproniazid; Levodopa; Male; Rats; Stereotyped Behavior | 1979 |
On certain relationships between gamma-aminobutyric acid (GABA) and dopaminergic agents in pentylenetetrazol convulsions.
Topics: Amantadine; Animals; Apomorphine; Dextroamphetamine; Ditiocarb; Dopamine; Drug Interactions; gamma-Aminobutyric Acid; Haloperidol; Levodopa; Male; Mice; Pentylenetetrazole; Seizures | 1978 |
Apomorphine stereotypies and transmitter mechanisms in the striatum. I. Changes in the apomorphine stereotypies caused by drugs acting on the GABA-ergic, dopaminergic and cholinergic transmission.
Topics: Aminooxyacetic Acid; Animals; Apomorphine; Behavior; Corpus Striatum; Diazepam; Ditiocarb; Dopamine; gamma-Aminobutyric Acid; Haloperidol; Humans; Levodopa; Male; Methyltyrosines; Mice; Parasympathetic Nervous System; Picrotoxin; Semicarbazides; Stereotyped Behavior; Synaptic Transmission | 1978 |
[Thyrotropin-releasing hormone (TRH): Enhancement of dopamine dependent circling behavior and its own circling-inducing effect in unilateral striatal lesioned animals (author's transl)].
Topics: Animals; Apomorphine; Corpus Striatum; Cyclic AMP; Dopamine; Drug Synergism; gamma-Aminobutyric Acid; In Vitro Techniques; Levodopa; Male; Mice; Motor Activity; Perfusion; Rats; Rotation; Thyrotropin-Releasing Hormone; Time Factors | 1979 |
The pharmacological and anatomical substrates of the amphetamine response in the rat.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Cerebral Cortex; Cocaine; Dextroamphetamine; Drinking Behavior; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Locomotion; Male; Neural Pathways; Norepinephrine; Rats; Receptors, Adrenergic; Stereotyped Behavior; Stimulation, Chemical; Substantia Nigra; Tyrosine 3-Monooxygenase | 1975 |
Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hydroxydopamines; Levodopa; Male; Movement; Nerve Degeneration; Neurons; Neurotransmitter Agents; Oxotremorine; Parkinson Disease, Secondary; Rats; Rotation; Stereotaxic Techniques; Substantia Nigra; Synaptic Transmission; Time Factors | 1975 |
Dopamine-induced neurogenic vasodilatation in isolated perfused muscle preparation of the dog.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Apomorphine; Atropine; Autonomic Fibers, Preganglionic; Blood Vessels; Diphenhydramine; Dogs; Dopamine; Dopamine Antagonists; Female; Ganglia, Autonomic; Haloperidol; Hindlimb; Histamine; In Vitro Techniques; Levodopa; Male; Muscles; Perfusion; Phentolamine; Reflex; Sympathetic Nervous System; Vascular Resistance | 1975 |
The role of dopamine and noradrenaline in temperature control of normal and reserpine-pretreated mice.
Topics: Amantadine; Animals; Apomorphine; Body Temperature; Body Temperature Regulation; Dextroamphetamine; Dopamine; Droxidopa; Esophagus; Female; Levodopa; Male; Mice; Mice, Inbred Strains; Norepinephrine; Reserpine; Time Factors | 1975 |
Opiates, prolactin, and the dopamine receptor.
Topics: Apomorphine; Bromocriptine; Chlorpromazine; Cyproheptadine; Heroin Dependence; Humans; Kinetics; Levodopa; Methadone; Morphine; Prolactin; Receptors, Dopamine | 1978 |
Aminergic and thermoregulatory mechanims in hypothalamic regulation of growth hormone in cats.
Topics: 18-Hydroxycorticosterone; 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Amines; Blood Glucose; Body Temperature Regulation; Carbidopa; Cats; Growth Hormone; Hypothalamus; Levodopa; Male; Mesencephalon; Norepinephrine; Phenoxybenzamine; Pimozide; Serotonin; Temperature | 1977 |
Effects of 3,4-dihydro-lH-1,4-oxazino[4,3-a] indoles, potential antidepressants, on biogenic amine uptake mechanisms and related activities.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Biogenic Amines; Brain; Drug Interactions; Indoles; Levodopa; Male; Medulla Oblongata; Mice; Myocardium; Norepinephrine; Oxazines; Oxotremorine; p-Hydroxyamphetamine; Rats; Reflex; Reserpine; Serotonin | 1977 |
Modulation of the tonic stretch reflex by monoamines.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Amines; Cats; Decerebrate State; Electromyography; Female; Levodopa; Male; Motor Neurons; Pimozide; Reflex; Serotonin | 1979 |
On some relationships between dopaminergic and serotoninergic mechanisms in pentylenetetrazol convulsions in albino mice.
Topics: 5-Hydroxytryptophan; Amantadine; Amphetamine; Animals; Apomorphine; Dopamine; Levodopa; Male; Mice; Pentylenetetrazole; Seizures; Serotonin | 1979 |
Apomorphine revived: fortified, prolonged, and improved therapeutical effect.
Topics: Aged; Alcoholism; Apomorphine; Benserazide; Capsules; Drug Combinations; History, 18th Century; History, 20th Century; Humans; Levodopa; Male; Substance-Related Disorders; Tablets | 1978 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Papio; Parasympatholytics; Physostigmine; Pimozide; Receptors, Dopamine; Reserpine; Syndrome; Tranquilizing Agents | 1977 |
Neurochemical investigations of the interaction of N,N-dimethyltryptamine with dopaminergic system in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain; Corpus Striatum; Dextroamphetamine; Dihydroxyphenylalanine; Dopamine; Female; Homovanillic Acid; Levodopa; Monoamine Oxidase; N,N-Dimethyltryptamine; Norepinephrine; Normetanephrine; Rats; Time Factors; Tryptamines; Tyramine | 1977 |
Dopamine receptors and sleep induction in man.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Receptors, Dopamine; Sleep; Sleep Stages; Time Factors; Vomiting | 1979 |
A study of growth hormone release in depression.
Topics: Adult; Apomorphine; Bipolar Disorder; Depression; Growth Hormone; Humans; Levodopa; Male; Middle Aged | 1979 |
[Role of the catecholaminergic mechanisms and of the caudate nucleus in the development of generalized convulsions caused by the parenteral administration of penicillin].
Topics: Animals; Apomorphine; Cats; Caudate Nucleus; Chlorpromazine; Electric Stimulation; Electroencephalography; Female; Haloperidol; Levodopa; Male; Penicillin G; Receptors, Adrenergic; Seizures; Time Factors | 1979 |
Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.
Topics: Animals; Apomorphine; Bromocriptine; Carbidopa; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Radioligand Assay; Rats; Receptors, Dopamine; Receptors, Drug; Spiperone | 1979 |
Central dopamine receptors regulate blood eosinophilia in the rat.
Topics: Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Benzyl Alcohols; Brain; Dihydroxyphenylalanine; Dopamine beta-Hydroxylase; Dose-Response Relationship, Drug; Eosinophils; Haloperidol; Hydrazines; Hypophysectomy; Leukocyte Count; Levodopa; Male; Phenylthiourea; Rats; Receptors, Dopamine | 1979 |
Movement disorders of aged rats: reversal by dopamine receptor stimulation.
Topics: Aging; Animals; Apomorphine; Levodopa; Male; Movement Disorders; Rats; Receptors, Dopamine; Swimming; Time Factors | 1979 |
Role of the caudate nucleus in production of dyskinesia [proceedings].
Topics: Animals; Apomorphine; Cats; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Electric Stimulation; Levodopa; Movement Disorders; Neural Pathways; Substantia Nigra; Tremor | 1979 |
Role of dopaminergic and noradrenergic mechanisms in Metrazole convulsions in mice.
Topics: Animals; Apomorphine; Benserazide; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Clonidine; Dopamine; Drug Interactions; Female; Haloperidol; Levodopa; Male; Methyltyrosines; Mice; Norepinephrine; Pentylenetetrazole; Phenoxybenzamine; Propranolol; Receptors, Dopamine; Reserpine; Seizures; Tetrabenazine | 1979 |
Growth-hormone and somatostatin effects on [75Se]selenomethionine uptake by the pancreas.
Topics: Animals; Apomorphine; Autoradiography; Carbon Radioisotopes; Dogs; Growth Hormone; Intestinal Mucosa; Kidney; Levodopa; Liver; Methionine; Mice; Pancreas; Radioisotopes; Selenium; Selenomethionine; Somatostatin | 1979 |
Influence of x-ray irradiation on the effects of apomorphine and L-dopa with respect to the dopamine level in rat brain and corpus striatum.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Corpus Striatum; Dopamine; Levodopa; Male; Radiation Injuries, Experimental; Rats; X-Rays | 1979 |
[Sleep: biochemical correlations and pharmacological considerations].
Topics: Acetylcholine; Animals; Apomorphine; Brain Chemistry; Carbidopa; Catecholamines; gamma-Aminobutyric Acid; Humans; Levodopa; Peptides; Serotonin; Serotonin Antagonists; Sleep; Vasopressins | 1979 |
[Selective dopaminergic regulation of stereotyped forms of aggressive and defensive behavior].
Topics: Aggression; Amphetamine; Animals; Apomorphine; Behavior; Chinchilla; Dopamine; Humans; Levodopa; Rabbits; Stereotyped Behavior | 1977 |
[Antagonism between L-DOPA and apomorphine in their effects on rat behavior].
Topics: Aggression; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Dopamine; Drug Antagonism; Humans; Levodopa; Male; Norepinephrine; Orientation; Rats; Receptors, Dopamine; Stereotyped Behavior | 1977 |
Clonazepam and dopamine-related stereotyped behavior.
Topics: Animals; Apomorphine; Behavior; Benzodiazepinones; Clonazepam; Dopamine; Drug Interactions; Ergot Alkaloids; Guinea Pigs; Humans; Levodopa; Male; Stereotyped Behavior; Time Factors | 1977 |
L-DOPA reversal of hyperdopaminergic behaviour.
Topics: Animals; Apomorphine; Behavior; Carbidopa; Dopamine; Humans; Levodopa; Male; Rats; Reserpine; Stereotyped Behavior | 1978 |
Influence of dopaminergic agonists upon body temperature and behavior of spontaneously hypertensive and normotensive rats.
Topics: Animals; Apomorphine; Behavior, Animal; Body Temperature; Carbidopa; Dopamine; Haloperidol; Humans; Hypertension; Levodopa; Male; Motor Activity; Rats; Stereotyped Behavior | 1978 |
Dopaminergic antagonists: effects of 1,2,3,4-tetrahydroisoquinoline and its N-methyl and N-propyl homologs on apomorphine- and L-dopa-induced behavioral effects in rodents.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Brain; Dopamine Antagonists; Humans; Isoquinolines; Levodopa; Male; Mice; Motor Activity; Rats; Stereotyped Behavior; Substantia Nigra; Time Factors | 1979 |
[Relationship between gnawing compulsion and central dopaminergic mechanism in guinea pigs (author's transl)].
Topics: Amphetamine; Animals; Apomorphine; Behavior; Benserazide; Dopamine; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Methyltyrosines; Pimozide; Stereotyped Behavior | 1979 |
Differential effects of L-dopa and apomorphine on glucagon secretion in man: evidence against central dopaminergic stimulation of glucagon.
Topics: Adult; Apomorphine; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glucagon; Growth Hormone; Humans; Insulin; Levodopa; Male; Prolactin; Receptors, Dopamine | 1977 |
The effect of dopaminergic drugs on pituitary hormone release in normal subjects.
Topics: Adult; Apomorphine; Bromocriptine; Chlorpromazine; Female; Humans; Levodopa; Pituitary Gland | 1977 |
Apomorphine-stimulated growth hormone release.
Topics: Adolescent; Adult; Apomorphine; Female; Growth Hormone; Humans; Levodopa; Male; Stimulation, Chemical | 1977 |
Levodopa-induced dopamine receptor hypersensitivity.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Receptors, Dopamine; Stereotyped Behavior | 1977 |
Hypokinesia produced by anterolateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Bromocriptine; Dopamine; Hydroxydopamines; Hypothalamus; Hypothalamus, Anterior; Levodopa; Male; Models, Neurological; Motor Activity; Norepinephrine; Piribedil; Rats; Receptors, Dopamine; Serotonin; Tyrosine | 1978 |
Neuroendocrine studies with dopamine agonists in schizophrenia.
Topics: Adult; Apomorphine; Growth Hormone; Humans; Levodopa; Male; Receptors, Dopamine; Schizophrenia | 1978 |
A method for mechanographical recording of muscle tone in the rat: the effect of some antiparkinsonian drugs on rigidity induced by reserpine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Bromocriptine; Carbidopa; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Male; Muscle Rigidity; Muscle Tonus; Myography; Rats; Reserpine | 1978 |
Repeated exposure of rats to the convulsant agent flurothyl enhances 5-hydroxytryptamine- and dopamine-mediated behavioural responses.
Topics: Animals; Apomorphine; Dopamine; Electroshock; Flurothyl; Levodopa; Male; Methamphetamine; Motor Activity; Rats; Serotonin; Stimulation, Chemical; Time Factors; Tranylcypromine | 1978 |
Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Brain; Catecholamines; Chemical Phenomena; Chemistry; Corpus Striatum; Dopamine; Levodopa; Lysergic Acid Diethylamide; Male; Metergoline; Norepinephrine; Rats; Receptors, Dopamine; Serotonin | 1978 |
The emetic action of L-dopa and its effect on the swallowing reflex in the cat.
Topics: Animals; Apomorphine; Cats; Deglutition; Electric Stimulation; Emetics; Female; Iproniazid; Laryngeal Nerves; Levodopa; Male | 1978 |
Suppression of prolactin by dopamine agonists in schizophrenics and controls.
Topics: Adult; Apomorphine; Chronic Disease; Depression, Chemical; Dopamine; Humans; Levodopa; Male; Prolactin; Schizophrenia | 1978 |
Adrenergic and dopaminergic control of growth hormone secretion in urethan anesthetized adult male rats.
Topics: Animals; Apomorphine; Clonidine; Dose-Response Relationship, Drug; Growth Hormone; Injections, Intraventricular; Levodopa; Male; Norepinephrine; Phentolamine; Pimozide; Prolactin; Rats; Sympatholytics; Sympathomimetics; Urethane | 1978 |
Apomorphine and L-DOPA lower ejaculation threshold in the male rat.
Topics: Animals; Apomorphine; Benserazide; Brain; Carboxy-Lyases; Ejaculation; Levodopa; Male; Pimozide; Rats; Receptors, Dopamine; Serotonin; Sexual Behavior, Animal | 1978 |
Antagonism of morphine-induced central stimulation in mice by small doses of catecholamine-receptor agonists.
Topics: Animals; Apomorphine; Brain; Clonidine; Dopamine; Levodopa; Male; Methyltyrosines; Mice; Morphine; Motor Activity; Norepinephrine; Parasympathomimetics | 1978 |
Receptor basis for dopaminergic supersensitivity in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Caudate Nucleus; Dopamine; Haloperidol; Homovanillic Acid; Humans; Levodopa; Middle Aged; Parkinson Disease; Putamen; Receptors, Dopamine; Synaptic Membranes | 1978 |
Mechanism of antiemetic action of penfluridol in the dog.
Topics: Administration, Oral; Animals; Antiemetics; Apomorphine; Dogs; Drug Antagonism; Female; Injections, Intravenous; Injections, Intraventricular; Levodopa; Male; Medulla Oblongata; Penfluridol; Piperidines | 1978 |
The role of biogenic amines in the regulation of growth hormone and corticotropin secretion in the trained conscious dog.
Topics: Adrenal Cortex Hormones; Animals; Apomorphine; Biogenic Amines; Blood Glucose; Carbidopa; Clonidine; Dogs; Growth Hormone; Levodopa; Male; Pimozide | 1978 |
Impaired responses of growth hormone and blood eosinophils to L-dopa in atopy [proceedings].
Topics: Apomorphine; Eosinophils; Female; Growth Hormone; Humans; Hypersensitivity; Leukocyte Count; Levodopa; Male | 1978 |
Drug effect on cholinergic mechanisms in the cerebral cortex.
Topics: Acetylcholine; Amphetamine; Animals; Apomorphine; Cats; Cerebral Cortex; Chlorpromazine; Choline O-Acetyltransferase; Cholinergic Fibers; Levodopa; Nerve Endings; Rats; Receptors, Dopamine | 1978 |
Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity.
Topics: 5,7-Dihydroxytryptamine; Animals; Apomorphine; Biogenic Amines; Brain; Carboxy-Lyases; Catecholamines; Dopamine; Dopamine beta-Hydroxylase; Hydroxydopamines; Levodopa; Male; Motor Activity; Rats; Serotonin; Tryptophan Hydroxylase | 1979 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; Levodopa; Parkinson Disease, Secondary; Piribedil; Rats; Reserpine; Tyrosine | 1975 |
Recovery from paradoxical growth hormone responses in acromegaly after transphenoidal selective adenomectomy.
Topics: Acromegaly; Adenoma; Adult; Apomorphine; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Gonadotropin-Releasing Hormone; Growth Hormone; Humans; Insulin; Levodopa; Luteinizing Hormone; Pituitary Neoplasms; Prolactin; Thyrotropin-Releasing Hormone | 1975 |
[Rapid and prolonged facilitation of stereotyped motor behavior (verticalization) induced by apomorphine in mice previously submitted to stimulation of dopaminergic receptors].
Topics: Animals; Apomorphine; Behavior; Behavior, Animal; Corpus Striatum; Dextroamphetamine; Dopamine; Humans; Hypothermia; Levodopa; Male; Metaraminol; Mice; Sensory Receptor Cells; Stereotyped Behavior; Time Factors | 1976 |
Normalization by antipsychotic drugs of biochemically induced abnormal behavior in rats.
Topics: Animals; Apomorphine; Avoidance Learning; Discrimination Learning; Dopamine; Levodopa; Male; Norepinephrine; Phenoxybenzamine; Pimozide; Rats | 1976 |
Drug-induced rotation in rats without lesions: behavioral and neurochemical indices of a normal asymmetry in nigro-striatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Corpus Striatum; Dextroamphetamine; Dominance, Cerebral; Dopamine; Female; Haloperidol; Humans; Levodopa; Norepinephrine; Rats; Scopolamine; Stereotyped Behavior; Substantia Nigra | 1976 |
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase.
Topics: Adenylyl Cyclases; Amphetamines; Animals; Apomorphine; Caudate Nucleus; Cycloheximide; Dopamine; Drug Interactions; Hydroxydopamines; In Vitro Techniques; Levodopa; Male; Methamphetamine; Motor Activity; Norepinephrine; Pentylenetetrazole; Poly I-C; Rats; Receptors, Dopamine; Sleep; Thyrotropin-Releasing Hormone; Tranylcypromine; Tryptophan | 1976 |
Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
Topics: Adult; Apomorphine; Growth Hormone; Humans; Levodopa; Male; Receptors, Dopamine; Schizophrenia | 1976 |
A neuropharmacological approach to experimental bruxism.
Topics: Animals; Apomorphine; Behavior, Animal; Bromocriptine; Bruxism; Drug Synergism; Levodopa; Male; Mastication; Methylphenidate; Piribedil; Rats; Scopolamine; Theophylline; Time Factors | 1977 |
Effects of dopaminergic agonists and antagonists of feeding in intact and 6-hydroxydopamine-treated rats.
Topics: Animals; Apomorphine; Benztropine; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Catecholamines; Cocaine; Dextroamphetamine; Dopamine; Dopamine Antagonists; Eating; Hydroxydopamines; Levodopa; Male; Methylphenidate; Methyltyrosines; Motor Activity; Rats; Spiperone; Telencephalon | 1977 |
Dopaminergic influences on swallowing.
Topics: Animals; Apomorphine; Deglutition; Dextroamphetamine; Dopamine; Evoked Potentials; Laryngeal Nerves; Levodopa; Male; Muscle Contraction; Muscles; Phenoxybenzamine; Rats; Salivation | 1977 |
Analysis of the mechanism of the protective activity of some sympathomimetic amines in experimental ulcers.
Topics: Amitriptyline; Amphetamine; Animals; Apomorphine; Butyrophenones; Catecholamines; Chlorpromazine; Cocaine; Levodopa; Morphine; Pimozide; Rats; Receptors, Adrenergic; Reserpine; Restraint, Physical; Stomach Ulcer; Sympathomimetics; Trifluperidol | 1977 |
Dopaminergic drugs and ovulation: studies on PMS-induced ovulation and changes in median eminence DA and NE turnover in immature female rats.
Topics: Animals; Apomorphine; Carbidopa; Dopamine; Ergot Alkaloids; Female; Gonadotropins, Equine; Hypothalamo-Hypophyseal System; Levodopa; Lysergic Acid Diethylamide; Median Eminence; Norepinephrine; Ovulation; Piribedil; Pregnancy; Rats; Receptors, Adrenergic; Receptors, Dopamine | 1977 |
Interelationships between dopaminergic and cholinergic systems in the cerebral cortex.
Topics: Acetylcholine; Animals; Apomorphine; Benserazide; Bromocriptine; Cats; Cerebral Cortex; Dopamine; Female; Haloperidol; Levodopa; Male; Parasympathetic Nervous System; Rats; Time Factors | 1977 |
Nonstriatal dopaminergic neurons: Section XI. Dopaminergic neurons and mental diseases: Introduction: dopaminergic neurons and mental diseases.
Topics: Apomorphine; Bromocriptine; Catecholamines; Depression; Dopamine; Homovanillic Acid; Humans; Levodopa; Mental Disorders; Neurons; Schizophrenia | 1977 |
Neuroendocrine assessment of dopaminergic activity in schizophrenia.
Topics: Adult; Apomorphine; Dopamine; Growth Hormone; Humans; Levodopa; Male; Schizophrenia | 1977 |
Effects of morphine and haloperidol on the electrical activity of rat nigrostriatal neurons.
Topics: Action Potentials; Animals; Apomorphine; Caudate Nucleus; Corpus Striatum; Haloperidol; Injections; Injections, Intravenous; Levodopa; Male; Morphine; Narcotic Antagonists; Neurons; Rats; Substantia Nigra; Time Factors | 1977 |
Striatal efferent fibers play a role in maintaining rotational behavior in the rat.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Mapping; Caudate Nucleus; Corpus Striatum; Diencephalon; Efferent Pathways; Hydroxydopamines; Levodopa; Male; Motor Activity; Putamen; Rats; Substantia Nigra | 1977 |
Dopamine agonists induce recovery from surgically-induced septal rage.
Topics: Amphetamines; Anger; Animals; Apomorphine; Behavior, Animal; Levodopa; Male; Piribedil; Rage; Rats; Receptors, Dopamine; Septal Nuclei; Time Factors | 1977 |
A neuroendocrine study of supersensitivity in tardive dyskinesia.
Topics: Adult; Apomorphine; Chronic Disease; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Prolactin; Receptors, Dopamine; Schizophrenia; Tranquilizing Agents | 1977 |
In vivo binding of 3H-pimozide in mouse striatum: effects of dopamine agonists and antagonists.
Topics: Animals; Apomorphine; Cerebellum; Cerebral Cortex; Corpus Striatum; Dextroamphetamine; Haloperidol; Homovanillic Acid; Levodopa; Male; Mice; Pimozide; Receptors, Dopamine; Sulpiride | 1977 |
Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
Topics: Amphetamine; Animals; Apomorphine; Bromocriptine; Drug Interactions; Ergolines; Humans; Hydroxydopamines; Levodopa; Male; Mice; Motor Activity; Rats; Receptors, Drug; Reserpine; Stereotyped Behavior; Substantia Nigra | 1976 |
[Effect of striatectomy on the course of corazole seizures in rats].
Topics: Animals; Apomorphine; Chlorpromazine; Corpus Striatum; Electroencephalography; Female; Haloperidol; Levodopa; Male; Myoclonus; Pentylenetetrazole; Rats; Seizures | 1976 |
On spinal noradrenaline receptor supersensitivity: correlation between nerve terminal densities and flexor reflexes various times after intracisternal 6-hydroxydopamine.
Topics: Animals; Apomorphine; Body Weight; Cell Count; Clonidine; Dose-Response Relationship, Drug; Hindlimb; Hydroxydopamines; Levodopa; Male; Nerve Endings; Nialamide; Rats; Receptors, Adrenergic; Reflex; Serotonin; Spinal Cord; Time Factors | 1976 |
Spontaneous firing rate of neurones in the prefrontal cortex of the rat: evidence for a dopaminergic inhibition.
Topics: Action Potentials; Animals; Apomorphine; Cerebral Cortex; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; Frontal Lobe; Levodopa; Male; Neural Inhibition; Neurons; Rats; Receptors, Dopamine; Spiperone | 1976 |
Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities.
Topics: Amitriptyline; Animals; Apomorphine; Biogenic Amines; Brain; Desipramine; Drug Synergism; Gastric Juice; Imipramine; In Vitro Techniques; Levodopa; Mice; Morpholines; Myocardium; Norepinephrine; Oxotremorine; Pupil; Rats; Reflex; Reserpine; Serotonin; Tyramine; Viloxazine | 1976 |
The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice.
Topics: Animals; Apomorphine; Clonidine; Dopamine; Drug Interactions; Exploratory Behavior; Levodopa; Male; Methyltyrosines; Mice; Mice, Inbred Strains; Motor Activity; Norepinephrine; Receptors, Drug; Reserpine; Stimulation, Chemical | 1976 |
Mescaline: its effects on learning rate and dopamine metabolism in goldfish (Carassius auratus).
Topics: Animals; Apomorphine; Avoidance Learning; Brain; Dopamine; Fluphenazine; Goldfish; Levodopa; Mescaline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Serotonin | 1976 |
[Interaction between L-dopa and other drugs].
Topics: Amantadine; Anti-Arrhythmia Agents; Apomorphine; Chlorpromazine; Drug Antagonism; Drug Interactions; Drug Synergism; Humans; Levodopa; Parkinson Disease; Tranquilizing Agents | 1976 |
Evidence for dopamine receptors mediating sedation in the mouse brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain; Dose-Response Relationship, Drug; Levodopa; Mice; Motor Activity; Pimozide; Receptors, Dopamine; Tranquilizing Agents | 1976 |
Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin.
Topics: Amantadine; Apomorphine; Growth Hormone; Humans; Levodopa; Parkinson Disease; Somatostatin | 1976 |
alpha and beta Dopamine receptors?
Topics: Apomorphine; Chorea; Haloperidol; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Torticollis | 1976 |
Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat.
Topics: Animals; Apomorphine; Benserazide; Clonidine; Dextroamphetamine; Dopamine; Female; Haloperidol; Hypophysectomy; Levodopa; Male; Methyltyrosines; Piribedil; Pituitary Gland; Prolactin; Rats; Reserpine; Sulpiride; Transplantation, Homologous | 1976 |
[Behavioral pharmacology of a new antidepressant, lopramine].
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Apomorphine; Avoidance Learning; Blepharoptosis; Body Temperature; Catalepsy; Dibenzazepines; Drug Synergism; Emotions; Humans; Imipramine; Lethal Dose 50; Levodopa; Male; Methamphetamine; Mice; Motor Activity; Muscle Relaxation; Oxotremorine; Physostigmine; Rats; Stereotyped Behavior | 1976 |
Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats.
Topics: Animals; Apomorphine; Denervation; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Humans; Hydroxydopamines; Hypothalamus; Levodopa; Male; Motor Activity; Nerve Degeneration; Parkinson Disease; Piperazines; Rats; Receptors, Dopamine; Stereotyped Behavior; Stimulation, Chemical | 1976 |
Effects of tandamine and pirandamine, new potential antidepressants, on the brain uptake of norepinephrine and 5-hydroxytryptamine and related activities.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents, Tricyclic; Apomorphine; Brain; Drug Synergism; Indenes; Indoles; Levodopa; Male; Mice; Norepinephrine; Oxotremorine; Rats; Reflex; Reserpine; Serotonin; Tyramine | 1976 |
A comparison of circling models for the detection of antiparkinson activity.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior; Brain; Dextroamphetamine; Dopamine; Haloperidol; Humans; Isoquinolines; Levodopa; Male; Methylphenidate; Methyltyrosines; Piperazines; Rats; Reserpine; Rotation; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra; Thalamic Nuclei | 1975 |
Role of the strio-pallidal system and motor cortex in induced circus movements in rats and cats.
Topics: Animals; Apomorphine; Brain Mapping; Cats; Chlorpromazine; Corpus Striatum; Dextroamphetamine; Drug Interactions; Female; Haloperidol; Levodopa; Locomotion; Male; Mesencephalon; Motor Cortex; Movement Disorders; Neural Pathways; Rats | 1975 |
Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Levodopa; Movement Disorders; Psychoses, Substance-Induced; Reaction Time; Receptors, Drug; Schizophrenia; Stereotyped Behavior; Substance-Related Disorders | 1975 |
Blockade of alpha-methyltyrosine-induced supersensitivity to apomorphine by chronic administration of L-dopa.
Topics: Animals; Apomorphine; Brain Chemistry; Diet; Dose-Response Relationship, Drug; Drug Hypersensitivity; Levodopa; Locomotion; Male; Methyltyrosines; Mice; Norepinephrine; Placebos; Receptors, Drug | 1975 |
Rotatory behavior induced in nigra-lesioned rats by N-propylnoraporphine, apomorphine, and levodopa.
Topics: Animals; Apomorphine; Aporphines; Atropine; Behavior, Animal; Brain Injuries; Carbidopa; Dose-Response Relationship, Drug; Drug Synergism; Hydroxydopamines; Levodopa; Male; Rats; Rotation; Substantia Nigra; Time Factors | 1975 |
Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice.
Topics: Animals; Apomorphine; Brain Chemistry; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxydopamines; Levodopa; Male; Mice; Motor Activity; Nerve Endings; Stereotyped Behavior; Time Factors | 1975 |
Catecholamine correlates of isolation-induced aggression in mice.
Topics: Aggression; Animals; Apomorphine; Brain Chemistry; Catecholamines; Dextroamphetamine; Disulfiram; Humans; Levodopa; Male; Mice; Motor Activity; Pimozide; Social Isolation | 1975 |
Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Guinea Pigs; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Antagonists; Humans; Hyperkinesis; Levodopa; Methylphenidate; Motor Activity; Movement Disorders; Phenethylamines; Piribedil; Rats; Stereotyped Behavior; Tyrosine | 1975 |
Behavioral correlates of dopaminergic supersensitivity.
Topics: Animals; Animals, Newborn; Apomorphine; Behavior; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxydopamines; Hypothalamus; Levodopa; Motor Activity; Nerve Degeneration; Rats; Receptors, Drug; Stereotyped Behavior; Substantia Nigra; Tranylcypromine; Tyrosine | 1975 |
Head-turning induced by electrical stimulation of the caudate nucleus and its antagonism by anti-parkinson drugs.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benztropine; Caudate Nucleus; Depression, Chemical; Electric Stimulation; Humans; Levodopa; Male; Rats; Stereotyped Behavior; Trihexyphenidyl | 1975 |
Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration.
Topics: Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine; Humans; Levodopa; Male; Mice; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Does chronic morphine treatment induce a supersensitivity of dopamine receptors in rat brain?
Topics: Animals; Apomorphine; Benserazide; Brain; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Levodopa; Male; Morphine; Probenecid; Rats; Receptors, Drug; Stereotyped Behavior; Substance Withdrawal Syndrome | 1975 |
Dopaminergic drugs antagonize the psychotomimetic effects of partial-agonist analgesics.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Benztropine; Cyclazocine; Dopamine; Dose-Response Relationship, Drug; Humans; Levallorphan; Levodopa; Male; Motor Activity; Naloxone; Piribedil; Rats; Rats, Inbred Strains; Stereotyped Behavior | 1975 |
The evaluation of anti-parkinson drugs on reserpine-induced rigidity in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Benztropine; Carbidopa; Hindlimb; Levodopa; Male; Methamphetamine; Muscle Rigidity; Rats; Reserpine; Scopolamine; Time Factors; Trihexyphenidyl | 1975 |
The influence of piribedil (ET495) on components of locomotor activity.
Topics: Amphetamine; Animals; Apomorphine; Brain; Clonidine; Dopamine; Levodopa; Male; Methoxyhydroxyphenylglycol; Mice; Motor Activity; Norepinephrine; Piperazines; Piribedil; Reserpine; Time Factors | 1975 |
The effect of dopaminergic stimulation and blockade on the nociceptive and antinociceptive responses of mice.
Topics: Analgesics; Animals; Apomorphine; Depression, Chemical; Dopamine; Haloperidol; Levodopa; Male; Mice; Morphine; Naloxone; Pain; Pimozide; Reaction Time; Receptors, Drug; Stimulation, Chemical | 1975 |
Enhancement of apomorphine-induced inhibition of vocalisation afterdischarge response by theophylline.
Topics: Animals; Apomorphine; Depression, Chemical; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Pain; Pimozide; Rats; Receptors, Drug; Theophylline; Vocalization, Animal | 1975 |
[Animal stereotypy and transmethylation of cerebral amines].
Topics: Amines; Amphetamine; Animals; Apomorphine; Brain; Levodopa; Movement Disorders; Piribedil; Rats; S-Adenosylmethionine | 1975 |
Influence of chemical stimulation of central dopaminergic system on the open field behaviour of rats.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benztropine; Brain; Dopamine; Levodopa; Male; Rats; Stimulation, Chemical | 1975 |
The dopamine hypothesis of schizophrenia. A critical analysis.
Topics: Acetylcholine; Amphetamine; Apomorphine; Cocaine; Dopamine; Electroconvulsive Therapy; gamma-Aminobutyric Acid; Humans; Levodopa; Methyldopa; Methyltyrosines; Models, Neurological; Psychoses, Substance-Induced; Schizophrenia; Tranquilizing Agents | 1975 |
Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior; Biogenic Amines; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Chlorpromazine; Clozapine; Corpus Striatum; Dextroamphetamine; Diazepam; Dopamine; Haloperidol; Humans; Hydroxydopamines; Levodopa; Male; Metoclopramide; Mice; Motor Activity; Pentobarbital; Phenoxybenzamine; Pimozide; Promethazine; Stereotyped Behavior; Tranquilizing Agents | 1975 |
[Behavior pharmacology of maprotiline, a new antidepressant].
Topics: Aggression; Amitriptyline; Animals; Anthracenes; Apomorphine; Behavior, Animal; Body Temperature; Catalepsy; Escape Reaction; Eyelids; Haloperidol; Humans; Imipramine; Levodopa; Maprotiline; Methamphetamine; Mice; Motor Activity; Oxotremorine; Physostigmine; Rats; Reserpine; Sleep; Tetrabenazine | 1975 |
Modification of the actions of some neuroactive drugs by growth hormone.
Topics: Animals; Apomorphine; Behavior, Animal; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Growth Hormone; Levodopa; Male; Mice; Oxotremorine; Parkinson Disease; Psychotropic Drugs; Tyrosine | 1976 |
The importance of 5-hydroxytryptamine for the induction of harmine tremor and its antagonism by dopaminergic agonists assessed by lesions of the midbrain raphe nuclei.
Topics: Alkaloids; Animals; Apomorphine; Dextroamphetamine; Harmine; Levodopa; Male; Mesencephalon; Nervous System Physiological Phenomena; Neural Pathways; Rats; Serotonin; Serotonin Antagonists; Tremor | 1976 |
Editorial: Alternatives to levodopa.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease | 1976 |
[Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease | 1992 |
[Feed-back regulation of presynaptic D2 receptors blockaded by l-stepholidine and l-tetrahydropalmatine].
Topics: Alkaloids; Animals; Apomorphine; Berberine; Berberine Alkaloids; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Levodopa; Male; Rats; Rats, Sprague-Dawley; Stereoisomerism | 1992 |
Effects of pharmacological manipulation of dopaminergic and cholinergic neurotransmission in genetically dystonic hamsters.
Topics: Acetylcholine; Animals; Apomorphine; Behavior, Animal; Carbidopa; Cricetinae; Dopamine; Drug Interactions; Dystonia; Haloperidol; Levodopa; Mesocricetus; Motor Activity; Mutation; Pilocarpine; Synaptic Transmission; Trihexyphenidyl | 1992 |
Levodopa challenge test in Parkinson's disease.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1992 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride | 1992 |
The effects of pertussis toxin on dopamine D2 and serotonin 5-HT1A autoreceptor-mediated inhibition of neurotransmitter synthesis: relationship to receptor reserve.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Brain; Dopamine Agents; GTP-Binding Proteins; Levodopa; Male; Neurotransmitter Agents; Pertussis Toxin; Piperidines; Quinolines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Ribose; Virulence Factors, Bordetella | 1992 |
Tetrahydrobiopterin-dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA.
Topics: Animals; Apomorphine; Behavior, Animal; Biopterins; Brain; Cell Line, Transformed; DNA; Female; Fibroblasts; Levodopa; Oxidopamine; Rats; Rats, Wistar; Stereotyped Behavior; Transfection; Tyrosine 3-Monooxygenase | 1992 |
Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery.
Topics: Administration, Oral; Aged; Apomorphine; Female; Hip Fractures; Humans; Infusion Pumps; Injections, Subcutaneous; Intestinal Obstruction; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats.
Topics: 4-Butyrolactone; Adrenergic alpha-Antagonists; Animals; Apomorphine; Dopamine Agents; Ergolines; Levodopa; Male; Piperidines; Prolactin; Quinolines; Rats; Rats, Sprague-Dawley | 1992 |
A new dopamine agonist in dopamine deprived systems: FCE 23884.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Levodopa; Male; Mice; Motor Activity; Reserpine; Time Factors | 1992 |
Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa.
Topics: Animals; Apomorphine; Autoradiography; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Dextroamphetamine; Female; Fetal Tissue Transplantation; In Vitro Techniques; Levodopa; Mesencephalon; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Time Factors | 1992 |
The clinical use of apomorphine in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Drug Administration Schedule; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Compliance | 1992 |
Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies | 1992 |
The dopaminergic response in multiple system atrophy.
Topics: Adult; Aged; Apomorphine; Atrophy; Brain Stem; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Terminology as Topic | 1992 |
Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
Topics: Adult; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1992 |
[Effect of apomorphine on the bladder of parkinsonian patients].
Topics: Aged; Aged, 80 and over; Apomorphine; Domperidone; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Urinary Bladder Diseases; Urodynamics | 1992 |
5-HT2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis.
Topics: Action Potentials; Amphetamines; Animals; Apomorphine; Carbidopa; Dopamine; Dopamine Antagonists; Fenclonine; Levodopa; Male; Neurons; Piperidines; Rats; Rats, Inbred Strains; Ritanserin | 1992 |
123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine; Tomography, Emission-Computed, Single-Photon | 1992 |
Delayed cyanide induced dystonia.
Topics: Adolescent; Adult; Apomorphine; Atrophy; Brain Damage, Chronic; Cerebral Cortex; Dystonia; Electroencephalography; Follow-Up Studies; Humans; Levodopa; Male; Neurologic Examination; Potassium Cyanide; Putamen; Reaction Time | 1992 |
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Carbidopa; Domperidone; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 1992 |
Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Female; Fetal Tissue Transplantation; Gliosis; Graft Survival; Immunohistochemistry; Levodopa; Mesencephalon; Neuroglia; Oxidopamine; Psychomotor Performance; Rats; Rats, Inbred Strains; Stereotaxic Techniques; Stereotyped Behavior; Sympathectomy, Chemical | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary | 1992 |
Apomorphine in malignant syndrome due to levodopa withdrawal.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Deoxyglucose; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Thalamic Nuclei | 1992 |
Apomorphine lowers dopamine synthesis for up to 48 h: implications for drug sensitization.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Apomorphine; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Drug Administration Schedule; Levodopa; Motor Activity; Rats; Rats, Inbred Strains; Reference Values; Time Factors; Tyrosine 3-Monooxygenase | 1991 |
The apomorphine test in parkinsonian syndromes.
Topics: Aged; Apomorphine; Diagnosis, Differential; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Muscular Atrophy; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Prognosis; Supranuclear Palsy, Progressive | 1991 |
Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Carbidopa; Corpus Striatum; Denervation; Drug Tolerance; Functional Laterality; Homovanillic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1991 |
Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aging; Analysis of Variance; Animals; Animals, Newborn; Apomorphine; Autoradiography; Corpus Striatum; Haloperidol; Hydroxydopamines; Levodopa; Mazindol; Motor Activity; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Stereotyped Behavior; Tritium | 1991 |
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Topics: Animals; Apomorphine; Body Weight; Carbidopa; Corpus Striatum; Drinking; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Nervous System; Oxidopamine; Parkinson Disease; Rats; Rotation; Stereotyped Behavior; Time Factors | 1991 |
Absorption of apomorphine by various routes in parkinsonism.
Topics: Absorption; Administration, Cutaneous; Administration, Oral; Administration, Sublingual; Animals; Apomorphine; Biological Availability; Drug Therapy, Combination; Infusions, Parenteral; Levodopa; Parkinson Disease | 1991 |
Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Bromocriptine; Clonidine; Dopamine Agents; Ergolines; Female; Levodopa; Motor Activity; Pergolide; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Sulpiride | 1990 |
Neurotransmitter and receptor alterations in the rat persistent dyskinesia model induced by iminodipropionitrile.
Topics: Animals; Apomorphine; Autoradiography; Benzazepines; Brain Chemistry; Bromocriptine; Ceruletide; Dyskinesia, Drug-Induced; Levodopa; Male; Neurotoxins; Neurotransmitter Agents; Nitriles; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Muscarinic | 1990 |
Choreic movements in the macaque monkey induced by kainic acid lesions of the striatum combined with L-dopa. Pharmacological, biochemical and physiological studies on neural mechanisms.
Topics: Animals; Apomorphine; Basal Ganglia; Behavior, Animal; Chorea; Corpus Striatum; Electrophysiology; Kainic Acid; Levodopa; Macaca fascicularis; Male; Methamphetamine; Movement; Nervous System; Neurons; Neurotransmitter Agents; Volition | 1990 |
Apomorphine test in parkinsonian syndromes.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease, Secondary | 1990 |
Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation.
Topics: Animals; Apomorphine; Brain Stem; Carbachol; Catalepsy; Dopamine Agents; Haloperidol; Injections; Injections, Subcutaneous; Levodopa; Male; Microinjections; Motor Activity; Rats; Rats, Inbred Strains; Reticular Formation; Stereotyped Behavior | 1990 |
Intranasal apomorphine in Parkinson's disease.
Topics: Administration, Intranasal; Aged; Apomorphine; Female; Humans; Levodopa; Male; Parkinson Disease; Pilot Projects | 1991 |
Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Benzylamines; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Endings; Neurotoxins; Norepinephrine | 1991 |
The motor response to sequential apomorphine in parkinsonian fluctuations.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychomotor Performance | 1991 |
Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
Topics: Administration, Oral; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Substance-Related Disorders | 1991 |
Buspirone in the treatment of levodopa induced dyskinesias.
Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
The motor response to repeated apomorphine administration in Parkinson's disease.
Topics: Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1991 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri | 1990 |
Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Corpus Striatum; Drug Interactions; Hydroxydopamines; Levodopa; Male; Morphine; Naltrexone; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Opioid | 1990 |
Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release?
Topics: Animals; Apomorphine; Benserazide; Brain Chemistry; Corpus Striatum; Dextroamphetamine; Dialysis; Dopamine; Extracellular Space; Kainic Acid; Levodopa; Male; Pargyline; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Synapses; Synaptic Transmission | 1990 |
Apomorphine in the diagnosis and treatment of parkinsonian tremor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor | 1990 |
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Disease Models, Animal; Dopamine; Hydrazines; Levodopa; Male; Methyltyrosines; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior | 1990 |
Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Carbidopa; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic | 1990 |
Subcutaneous apomorphine in the treatment of Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
[Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Disorders | 1990 |
['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
Topics: Aged; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Marijuana for parkinsonian tremor.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor | 1990 |
The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
Topics: Aged; Apomorphine; Dopamine; Humans; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1990 |
Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Drug Tolerance; Ergolines; Humans; Infusion Pumps; Levodopa; Lisuride; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Induction of dyskinesias.
Topics: Animals; Apomorphine; Delayed-Action Preparations; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1990 |
Computerized rotometer apparatus for recording circling behavior.
Topics: Animals; Apomorphine; Carbidopa; Computers; Dextroamphetamine; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Psychology, Experimental; Rats; Rats, Inbred Strains; Software; Stereotyped Behavior | 1989 |
Side-effects of subcutaneous apomorphine in Parkinson's disease.
Topics: Apomorphine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Apomorphine test for dopaminergic responsiveness.
Topics: Apomorphine; Diagnosis, Differential; Double-Blind Method; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1989 |
Motor response following repeated apomorphine administration is reduced in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1989 |
Dihydropyridine calcium channel antagonists as antidepressant drugs in mice and rats.
Topics: Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Body Temperature; Calcium Channel Blockers; Clonidine; Dihydropyridines; Hypnotics and Sedatives; Immobilization; Levodopa; Male; Mice; Rats; Rats, Inbred Strains; Reserpine; Species Specificity | 1989 |
Subcutaneous apomorphine in Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Comparative study of sulpiride and haloperidol on dopamine turnover in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain; Dopamine; Haloperidol; Levodopa; Male; Rats; Rats, Inbred Strains; Sulpiride | 1989 |
Continuous and intermittent levodopa differentially affect basal ganglia function.
Topics: Animals; Apomorphine; Basal Ganglia; Glutamate Decarboxylase; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1989 |
Peripheral pharmacokinetics of apomorphine in humans.
Topics: Adult; Aged; Apomorphine; Dopamine; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior | 1989 |
The effects on central dopamine function of chronic L-dopa (methyl ester hydrochloride) treatment of mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Body Temperature; Bromocriptine; Dextroamphetamine; Dopamine; Levodopa; Mice; Mice, Inbred Strains; Motor Activity; Receptors, Dopamine; Stereotyped Behavior | 1989 |
Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Topics: Aged; Apomorphine; Carbidopa; Drug Resistance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1989 |
Dopamine and L-dopa: inhibition of thyrotropin-stimulated thyroidal thyroxine release.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Atropine; Bucladesine; Carbidopa; Cyclic AMP; Dopamine; Dopamine beta-Hydroxylase; Female; Levodopa; Mice; Receptors, Adrenergic, alpha; Receptors, Dopamine; Sulpiride; Thyroid Gland; Thyrotropin; Thyroxine | 1986 |
Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium.
Topics: Animals; Anti-Anxiety Agents; Apomorphine; Behavior, Animal; Benzodiazepines; Dextroamphetamine; Dibenzocycloheptenes; Dopamine; Levodopa; Lithium; Male; Mice | 1985 |
Acute cyanide intoxication and central transmitter systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids; Animals; Apomorphine; Brain; Cyanides; Cyclic GMP; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Levodopa; Male; Neurotransmitter Agents; Norepinephrine; Rats; Rats, Inbred Strains; Spiperone | 1985 |
Differential effect of repeated treatment with L-dopa on dopamine-D1 or -D2 receptors.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone | 1986 |
An in vivo pharmacological method for the quantitative evaluation of the central effects of alpha 1 adrenoceptor agonists and antagonists.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amphetamine; Animals; Apomorphine; Brain; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Male; Myoclonus; Nalidixic Acid; Naphthyridines; Rats; Rats, Inbred Strains; Stereoisomerism | 1986 |
The effect of neurotransmitters on cataleptic behavior induced by PG D2 in rats.
Topics: Acetylcholine; Amantadine; Animals; Apomorphine; Catalepsy; Dopamine; Fenclonine; Injections, Intraventricular; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Norepinephrine; Prostaglandin D2; Prostaglandins D; Rats; Rats, Inbred Strains; Serotonin; Time Factors | 1987 |
Apomorphine infusion for motor fluctuations in Parkinson's disease.
Topics: Apomorphine; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 1987 |
Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
Topics: 4-Butyrolactone; Adrenergic alpha-Antagonists; Animals; Apomorphine; Corpus Striatum; Dihydroxyphenylalanine; Homeostasis; Hydrazines; Levodopa; Male; Piperidines; Quinolines; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1987 |
Subcutaneous apomorphine in parkinsonian on-off oscillations.
Topics: Adult; Aged; Apomorphine; Domperidone; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1988 |
Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine.
Topics: Aged; Apomorphine; Drug Therapy, Combination; Eructation; Esophageal Motility Disorders; Esophagus; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peristalsis | 1989 |
Dopamine receptor changes in response to prolonged treatment with L-dopa.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Benzazepines; Carbidopa; Corpus Striatum; Dopamine; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Spiperone; Stereotyped Behavior; Substantia Nigra; Sulpiride | 1986 |
Induction and reversal of dopamine dyskinesia in rat, cat, and monkey.
Topics: Animals; Apomorphine; Brain; Cats; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Motor Activity; Muscimol; Nomifensine; Piribedil; Rats; Receptors, Dopamine; Receptors, GABA-A; Stereotyped Behavior | 1985 |
A study of the mediator spectrum of delta-9 tetrahydrocanabinol effects on cerebral bioelectric activity.
Topics: Animals; Apomorphine; Cats; Cerebral Cortex; Conditioning, Psychological; Dopamine; Dronabinol; Electroencephalography; Evoked Potentials, Visual; Fenclonine; Levodopa; Methyltyrosines; Methysergide; Norepinephrine; Serotonin; Somatosensory Cortex; Sympathomimetics; Visual Cortex | 1985 |
Influence of some dopaminoceptor agents on nitrazepam-induced sleep in the domestic fowl (Gallus domesticus) and rats.
Topics: Aminooxyacetic Acid; Animals; Apomorphine; Chickens; Dopamine; Dose-Response Relationship, Drug; Electroencephalography; Electromyography; Haloperidol; Levodopa; Male; Nitrazepam; Norepinephrine; Phentolamine; Pimozide; Rats; Receptors, Dopamine; Receptors, GABA-A; Sleep; Tetrahydronaphthalenes | 1986 |
Suppressive effects of intraventricular injected dopamine and nomifensine on muricide induced by thiamine deficiency.
Topics: Aggression; Animals; Apomorphine; Dopamine; Hydroxydopamines; Injections, Intraventricular; Levodopa; Male; Mice; Nomifensine; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Thiamine Deficiency | 1987 |
L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.
Topics: Animals; Apomorphine; Carbidopa; Corpus Striatum; Denervation; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
Circling behavior in normoxic or hypoxic rats with unilateral 6-OHDA nigrostriatal lesion. Part 1. Effects of apomorphine and L-dopa.
Topics: Animals; Apomorphine; Corpus Striatum; Hydroxydopamines; Hypoxia; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1987 |
Circling behaviour in rats with unilateral lesions of the nigrostriatum induced by 6-hydroxydopamine: changes induced by oral administration of cytidine-5'-diphosphocholine.
Topics: Administration, Oral; Amphetamine; Animals; Apomorphine; Behavior, Animal; Choline; Corpus Striatum; Cytidine Diphosphate Choline; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1987 |
Reversal of the increase in apomorphine-induced stereotypy and aggression in REM sleep deprived rats by dopamine agonist pretreatments.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Bromocriptine; Carbidopa; Dopamine; Imipramine; Levodopa; Male; Nomifensine; Rats; Rats, Inbred Strains; Sleep Deprivation; Sleep, REM; Stereotyped Behavior | 1988 |
Social, motor, and autonomic signs of morphine withdrawal: differential sensitivities to catecholaminergic drugs in mice.
Topics: Animals; Apomorphine; Autonomic Nervous System; Catecholamines; Clonidine; Cocaine; Dextroamphetamine; Levodopa; Mice; Mice, Inbred Strains; Morphine Dependence; Psychomotor Performance; Reaction Time; Social Behavior; Substance Withdrawal Syndrome | 1988 |
The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems.
Topics: Adult; Aged; Apomorphine; Blood Pressure; Bromocriptine; Cardiovascular System; Catecholamines; Dopamine; Dopamine beta-Hydroxylase; Female; Heart Rate; Hemodynamics; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Parkinson Disease; Pulse; Sympathetic Nervous System | 1985 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Carotid Artery, Internal; Disease Models, Animal; Dominance, Cerebral; Dopamine; Homovanillic Acid; Injections, Intra-Arterial; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Pyridines | 1986 |
Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Ergolines; Levodopa; Lisuride; Male; Motor Activity; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
Diurnal responsiveness to apomorphine.
Topics: Aged; Apomorphine; Circadian Rhythm; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1987 |
Partial protection against hyperbaric oxygen induced convulsions by dopaminergic agents in mice: possible involvement of autoreceptors?
Topics: Animals; Antiparkinson Agents; Apomorphine; Body Temperature; Dose-Response Relationship, Drug; Haloperidol; Hyperbaric Oxygenation; Levodopa; Male; Mice; Mice, Inbred CBA; Piperidines; Reaction Time; Receptors, Dopamine; Respiration; Seizures | 1987 |
Continuous dopaminergic stimulation in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Humans; Levodopa; Lisuride; Parkinson Disease | 1987 |
Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists.
Topics: 4-Butyrolactone; Animals; Apomorphine; Corpus Striatum; Indoles; Levodopa; Male; Quinolines; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1986 |
Studies on the involvement of dopamine D-1 and D-2 receptors in the anticonvulsant effect of dopamine agonists in various rodent models of epilepsy.
Topics: Animals; Anticonvulsants; Apomorphine; Female; Gerbillinae; Kindling, Neurologic; Levodopa; Lisuride; Male; Mice; Oxazines; Rats; Receptors, Dopamine; Stimulation, Chemical | 1986 |
Differential changes in dopaminergic receptor sensitivity induced by agonist drugs.
Topics: Animals; Apomorphine; Benserazide; Brain Chemistry; Catalepsy; Drug Therapy, Combination; Haloperidol; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred Strains; Receptors, Dopamine | 1985 |
Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Bromocriptine; Corpus Striatum; Dopamine; Haloperidol; Levodopa; Male; Mice; Mice, Inbred C57BL; Nomifensine; Pyridines | 1985 |
Pharmacological activation of locomotor patterns in larval and adult frog spinal cords.
Topics: 2-Aminoadipic Acid; 5-Hydroxytryptophan; Animals; Apomorphine; Aspartic Acid; Benserazide; Clonidine; In Vitro Techniques; Larva; Levodopa; Locomotion; N-Methylaspartate; Nialamide; Rana catesbeiana; Rana pipiens; Spinal Cord | 1985 |
A pre-positron emission tomography study of L-3,4-dihydroxy-[3H]phenylalanine distribution in the rat.
Topics: Animals; Apomorphine; Autoradiography; Brain; Corpus Striatum; Desipramine; Dopamine; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra; Tissue Distribution; Tomography, Emission-Computed | 1985 |
Influences of catecholamines on growth hormone release in female goldfish, Carassius auratus.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Carbidopa; Catecholamines; Cyprinidae; Dopamine; Female; Goldfish; Growth Hormone; Hydroxydopamines; Levodopa; Methyltyrosines; Norepinephrine; Oxidopamine; Phentolamine; Preoptic Area | 1985 |
[Effect of dopaminergic pharmacological agents on thyrotropic hormone secretion by the hypophysis when stimulated with thyrotropin-releasing hormone].
Topics: Animals; Apomorphine; Bromocriptine; Carbidopa; Dopamine; Dopamine Antagonists; Haloperidol; Levodopa; Male; Pituitary Gland; Rats; Thyrotropin; Thyrotropin-Releasing Hormone | 1985 |
Simple method for evaluation of stimulatory effect of drugs on presynaptic dopamine receptors in mice.
Topics: Animals; Apomorphine; Haloperidol; Hydrazines; Hydroxydopamines; Levodopa; Male; Mice; Mice, Inbred Strains; Oxidopamine; Receptors, Dopamine | 1985 |
Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Topics: Apomorphine; Bromocriptine; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Metoclopramide; Monitoring, Physiologic; Neurosecretory Systems; Prolactin; Receptors, Dopamine; Schizophrenia; Selegiline; Time Factors | 1985 |
Dopamine agonists suppress visual-cortical reflex myoclonus.
Topics: Aged; Apomorphine; Atrophy; Carbidopa; Cerebellum; Drug Therapy, Combination; Electromyography; Epilepsies, Myoclonic; Ergolines; Evoked Potentials, Somatosensory; Evoked Potentials, Visual; Female; Humans; Levodopa; Lisuride; Olivary Nucleus; Photic Stimulation; Pons; Reflex; Visual Cortex | 1985 |
Effect of hypophysectomy and subsequent prolactin administration on hypothalamic 5-hydroxytryptamine synthesis in ovariectomized rats.
Topics: Animals; Apomorphine; Castration; Female; Hydrazines; Hypophysectomy; Hypothalamus; Levodopa; Median Eminence; Prolactin; Rats; Rats, Inbred Strains; Serotonin | 1985 |
The role of dopamine in the formation of gastric ulcers in rats.
Topics: Animals; Apomorphine; Bromocriptine; Domperidone; Dopamine; Female; Haloperidol; Levodopa; Male; Rats; Rats, Inbred Strains; Stomach Ulcer; Sulpiride | 1985 |
The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Corpus Striatum; Dextroamphetamine; Haloperidol; Levodopa; Male; Methyltyrosines; Mice; Motor Activity; Receptors, Dopamine; Reserpine; Spiperone | 1985 |
Influence of noncholinergic drugs on rat striatal acetylcholine levels.
Topics: Acetylcholine; Acetylcholinesterase; Acetyltransferases; Amantadine; Animals; Anti-Anxiety Agents; Apomorphine; Benzodiazepines; Biological Assay; Brain Chemistry; Choline; Corpus Striatum; Depression, Chemical; Haloperidol; Levodopa; Male; Methamphetamine; Rats; Rats, Inbred Strains; Reserpine; Stimulation, Chemical; Tyrosine 3-Monooxygenase | 1974 |
L-dopa hypotension in dogs: evidence for mediation through 5-HT release.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Brain Chemistry; Carbidopa; Chlorpromazine; Depression, Chemical; Dogs; Drug Interactions; Female; Fenclonine; Haloperidol; Heart Rate; Levodopa; Male; Methysergide; Monoamine Oxidase Inhibitors; Norepinephrine; Reserpine; Serotonin; Time Factors; Yohimbine | 1974 |
Changing the actions of neuroactive drugs by changing brain protein synthesis.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Behavior, Animal; Brain; Caudate Nucleus; Chloramphenicol; Cyclic AMP; Cycloheximide; Depression, Chemical; Dopamine; Levodopa; Mice; Motor Activity; Nerve Tissue Proteins; Oxotremorine; Poly I-C; Puromycin; Receptors, Adrenergic; Receptors, Cholinergic; Stimulation, Chemical | 1974 |
Mechanisms involved in the control of extrapyramidal dysfunctions and in striatal dopamine synthesis.
Topics: Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Bucladesine; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Depression, Chemical; Dopamine; Drug Therapy, Combination; Haloperidol; Haplorhini; Levodopa; Receptors, Drug; Stimulation, Chemical; Tremor | 1974 |
The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Apomorphine; Dioxoles; Drug Evaluation; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Piperazines; Pyrimidines; Time Factors | 1974 |
Unexpected findings with apomorphine and their possible consequences.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Levodopa; Movement Disorders; Parkinson Disease; Structure-Activity Relationship; Uremia | 1974 |
Short- and long-term approaches to the "on-off" phenomenon.
Topics: Apomorphine; Carbidopa; Dietary Proteins; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
Dopamine receptor in the reward system of the rat.
Topics: Amantadine; Animals; Apomorphine; Benzyl Compounds; Cortical Synchronization; Desipramine; Dihydroxyphenylalanine; Dopamine; Electrodes, Implanted; Electroencephalography; Haloperidol; Hydrazines; Hypothalamus; Levodopa; Male; Rats; Receptors, Drug; Reward; Self Stimulation; Time Factors | 1974 |
The effects of L0dopa, clonidine, and apomorphine on the acoustic startle reaction in rats.
Topics: Acoustic Stimulation; Animals; Apomorphine; Brain Chemistry; Brain Stem; Cerebral Cortex; Clonidine; Corpus Striatum; Diencephalon; Dopamine; Drug Interactions; Hydroxyindoleacetic Acid; Levodopa; Male; Norepinephrine; Rats; Receptors, Drug; Reflex, Startle; Reserpine; Serotonin; Stimulation, Chemical | 1974 |
Levodopa, manganese, and degenerations of the brain.
Topics: Administration, Oral; Animals; Apomorphine; Blood Urea Nitrogen; Brain Diseases; Carbon Radioisotopes; Chemical Phenomena; Chemistry; Chronic Disease; Dietary Proteins; Dopamine; Drug Therapy, Combination; Growth Hormone; Humans; Injections; Levodopa; Manganese Poisoning; Movement Disorders; Neutron Activation Analysis; Parkinson Disease; Psychoses, Substance-Induced; Radioisotopes | 1974 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Electric Stimulation; Electromyography; Feeding and Eating Disorders; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Motor Neurons; Muscle Contraction; Nerve Degeneration; Neural Pathways; Parkinson Disease; Parkinson Disease, Secondary; Perceptual Disorders; Rats; Reflex, Stretch; Substantia Nigra | 1974 |
Effect of L-DOPA and analogues on central dopamine and noradrenaline mechanisms.
Topics: 5-Hydroxytryptophan; Acetamides; Animals; Apomorphine; Brain Chemistry; Clonidine; Corpus Striatum; Dopamine; Hydrazines; Levodopa; Methyldopa; Methyltyrosines; Movement; Nialamide; Norepinephrine; Octopamine; Rats; Receptors, Drug; Reflex; Reserpine; Spinal Cord; Stimulation, Chemical; Tyramine; Tyrosine | 1974 |
Dopamine agonists and Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Brain; Bromocriptine; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Neurons; Parkinson Disease; Pergolide; Piribedil; Receptors, Dopamine | 1984 |
Effects of dopaminergic and cholinergic drugs. naloxone and l-prolyl-leucyl-glycinamide on LSD-induced catalepsy.
Topics: Animals; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Humans; Levodopa; Lysergic Acid Diethylamide; Male; MSH Release-Inhibiting Hormone; Naloxone; Parasympathomimetics; Rats; Synaptic Transmission; Time Factors | 1980 |
The functional role of the noradrenergic neurons in the thermoregulatory circuits in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Biogenic Amines; Body Temperature Regulation; Brain; Bromocriptine; Female; Hydroxydopamines; Kinetics; Levodopa; Male; Mice; Mice, Inbred Strains; Neurons; Norepinephrine; Piribedil | 1981 |
Increased responsiveness to apomorphine after REM sleep deprivation: supersensitivity of dopamine receptors or increase in dopamine turnover?
Topics: Aggression; Animals; Apomorphine; Dopamine; Humans; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Sleep Deprivation; Sleep, REM | 1981 |
Stereoselective opiate antagonist induced hyperalgesia: evidence for a dopaminergic involvement.
Topics: Animals; Apomorphine; Dopamine; Injections, Intraventricular; Levodopa; Male; Mice; Naloxone; Narcotic Antagonists; Nomifensine; Pain; Tetrabenazine | 1982 |
Chronic L-DOPA-pretreatment of rats: an electrophysiological and biochemical study in the basal ganglia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Basal Ganglia; Benserazide; Corpus Striatum; Dextroamphetamine; Dopamine; Evoked Potentials; Homovanillic Acid; Levodopa; Male; Neurons; Rats; Rats, Inbred Strains; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission; Tyrosine 3-Monooxygenase | 1982 |
Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
Topics: Animals; Anti-Anxiety Agents; Apomorphine; Buspirone; Corpus Striatum; Dopamine; Female; Kinetics; Levodopa; Male; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Synaptosomes; Tyrosine 3-Monooxygenase | 1983 |
Effects of dopaminergic agents on monoamine levels and motor behaviour in planaria.
Topics: Animals; Apomorphine; Dopamine; Haloperidol; Levodopa; Motor Activity; Norepinephrine; Planarians; Serotonin; Turbellaria | 1983 |
Possible anomalous behaviour of apomorphine in relation to other dopamine receptor agonists.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Corpus Striatum; Female; Homovanillic Acid; Levodopa; Rats; Rats, Inbred Strains; Receptors, Dopamine; Tetrahydronaphthalenes | 1983 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
The relative importance of dopamine and norepinephrine in mediating locomotor activity.
Topics: Adrenergic Antagonists; Amphetamines; Animals; Apomorphine; Biomechanical Phenomena; Brain Chemistry; Catecholamines; Clonidine; Corpus Striatum; Dopamine; Droxidopa; Isoproterenol; Levodopa; Limbic System; Locomotion; Neural Pathways; Neurotransmitter Agents; Norepinephrine; Nucleus Accumbens; Propranolol; Receptors, Dopamine; Reserpine; Serotonin; Serotonin Antagonists; Substantia Nigra; Tetrahydronaphthalenes | 1983 |
In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-DOPA.
Topics: Animals; Apomorphine; Benserazide; Binding Sites; Cell Membrane; Corpus Striatum; Dopamine; Hydrazines; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Tetrahydronaphthalenes; Tyrosine 3-Monooxygenase | 1984 |
Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Behavior, Animal; Blepharoptosis; Catalepsy; Fenclonine; Fenfluramine; Humans; Indoles; Levodopa; Male; Mice; Molindone; Monoamine Oxidase Inhibitors; p-Chloroamphetamine; Rats; Reserpine; Stereotyped Behavior; Tryptamines; Tryptophan | 1984 |
Prolactin-releasing effect of zetidoline, a new neuroleptic agent, in the rat.
Topics: Animals; Antipsychotic Agents; Apomorphine; Chlorpromazine; Estrus; Female; Haloperidol; Imidazoles; Levodopa; Male; Pregnancy; Prolactin; Rats; Rats, Inbred Strains | 1984 |
Spasmodic torticollis and other idiopathic torsion dystonias. Medical management.
Topics: Adrenergic Agents; Amantadine; Antipsychotic Agents; Apomorphine; Benzodiazepines; Carbamazepine; Dystonia; Humans; Levodopa; Parasympatholytics; Torsion Abnormality; Torticollis | 1984 |
Behavioral and neurochemical effects of apomorphine in the cat.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Brain Chemistry; Cats; Dose-Response Relationship, Drug; Drug Tolerance; Female; Fenclonine; Levodopa; Lysergic Acid Diethylamide; Male; Receptors, Serotonin | 1982 |
[Effect of tetrahydroberberine on blockade of pre- and postsynaptic dopamine receptors (author's transl)].
Topics: 4-Butyrolactone; Animals; Apomorphine; Berberine; Berberine Alkaloids; Corpus Striatum; Hypnotics and Sedatives; Levodopa; Rats; Receptors, Dopamine | 1982 |
[Role of dopamine receptors in the mechanism of formation of stress-induced stomach lesions].
Topics: Animals; Apomorphine; Female; Gastrointestinal Hemorrhage; Humans; Levodopa; Male; Metoclopramide; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Stomach Ulcer; Stress, Psychological; Sulpiride; Vagotomy | 1984 |
Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice.
Topics: Amantadine; Aminooxyacetic Acid; Amphetamine; Animals; Apomorphine; Baclofen; Dopamine; Electroshock; Female; Fluphenazine; gamma-Aminobutyric Acid; Haloperidol; Hydroxybutyrates; Levodopa; Male; Mice; Phenobarbital; Phenytoin; Receptors, Neurotransmitter; Seizures | 1980 |
L-dopa mediated accumulation of cyclic AMP in isolated rabbit retinae in vitro. Effects of light and/or pharmacological factors.
Topics: Animals; Apomorphine; Cyclic AMP; Dopamine; Drug Synergism; Female; Levodopa; Light; Male; Potassium; Rabbits; Retina | 1982 |
Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
Topics: Apomorphine; Brain; Bromocriptine; Humans; Levodopa; Parkinson Disease; Prolactin; Receptors, Dopamine; Receptors, Opioid; Thyrotropin-Releasing Hormone | 1983 |
Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Bromocriptine; Corpus Striatum; Dopamine; Levodopa; Male; Muridae; Receptors, Dopamine; Synaptic Transmission | 1983 |
[A long-term qualitative behavioral change following chronic methamphetamine administration in Japanese monkeys (Macaca fuscata)].
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Behavior, Animal; Cocaine; Dose-Response Relationship, Drug; Levodopa; Macaca; Male; Methamphetamine | 1983 |
Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): a summary of studies on volunteers.
Topics: Apomorphine; Bromocriptine; Dopamine; gamma-Aminobutyric Acid; Growth Hormone; Humans; Levodopa; Phenethylamines; Receptors, Dopamine; Selegiline; Synapses | 1983 |
Influence of levodopa, apomorphine and 3,4-dihydroxyphenylserine (DOPS) on strychnine-induced seizures in mice.
Topics: Animals; Apomorphine; Droxidopa; Levodopa; Mice; Phentolamine; Propranolol; Seizures; Serine; Strychnine | 1984 |
Influence of dopamine, levodopa and apomorphine on maximal electroconvulsive seizure in the domestic fowl (Gallus domesticus).
Topics: Age Factors; Animals; Apomorphine; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Chickens; Dopamine; Drug Antagonism; Electroshock; Haloperidol; Levodopa; Male; Pimozide; Rats; Seizures; Species Specificity | 1984 |
L-dopa and apomorphine disrupt long- but not short-behavioural chains.
Topics: Agonistic Behavior; Animals; Apomorphine; Behavior, Animal; Carnivora; Ferrets; Haloperidol; Levodopa; Male; Receptors, Dopamine; Sexual Behavior, Animal; Territoriality | 1984 |
Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Body Weight; Brain Chemistry; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Motor Activity; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1984 |
Chronic L-dopa treatment of rats and mice does not change the sensitivity of post-synaptic dopamine receptors.
Topics: Animals; Apomorphine; Benserazide; Humans; Levodopa; Male; Methyltyrosines; Mice; Motor Activity; Rats; Receptors, Dopamine; Reserpine; Stereotyped Behavior | 1983 |
Cholinergic receptor control mechanisms for L-dopa, apomorphine, and clonidine-induced growth hormone secretion in man.
Topics: Adult; Apomorphine; Benzodiazepinones; Clonidine; Growth Hormone; Humans; Kinetics; Levodopa; Male; Parasympatholytics; Pirenzepine; Prolactin; Receptors, Cholinergic | 1983 |
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.
Topics: Acetylcholine; Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Physostigmine; Time Factors | 1984 |
Hypothalamic self-stimulation: the role of dopamine and possible relations to neocortical slow wave activity.
Topics: Animals; Apomorphine; Cerebral Cortex; Conditioning, Operant; Dextroamphetamine; Dopamine; Electric Stimulation; Evoked Potentials; Hypothalamic Area, Lateral; Levodopa; Male; Motor Activity; Rats; Reserpine; Self Stimulation | 1984 |
Effects of some gamma-aminobutyric acid (GABA)-ergic drugs on the dopaminergic control of human growth hormone secretion.
Topics: Adult; Apomorphine; Baclofen; Diazepam; Dopamine; gamma-Aminobutyric Acid; Growth Hormone; Humans; Levodopa; Male; Valproic Acid | 1980 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Effects of lithium on behaviour and central monoamines.
Topics: Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Brain; Catecholamines; Clonidine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Lithium; Locomotion; Mice; Motor Activity; Rats | 1980 |
Chronic L-DOPA treatment of mice: a behavioural and biochemical study.
Topics: Animals; Apomorphine; Benserazide; Body Temperature Regulation; Brain; Clonidine; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Male; Mice; Motor Activity; Norepinephrine; Substance Withdrawal Syndrome | 1981 |
Pharmacologic manipulations of brain catecholamines and the behavior of Callithrix jacchus (marmoset).
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Callitrichinae; Catecholamines; Female; Haloperidol; Levodopa; Male; Methamphetamine; Methyltyrosines | 1981 |
Effects of L-deprenyl on human growth hormone secretion.
Topics: Adult; Apomorphine; Growth Hormone; Humans; Kinetics; Levodopa; Male; Phenethylamines; Selegiline; Tryptophan | 1981 |
The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
Topics: Animals; Apomorphine; Bromocriptine; Butyrophenones; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; Humans; Levodopa; Male; Muridae; Receptors, Dopamine; Spiperone; Stereotyped Behavior | 1982 |
Interrelations between dopaminergic and GABA-ergic transmitter mechanisms in apomorphine stereotypy.
Topics: Aminooxyacetic Acid; Animals; Apomorphine; Dopamine; gamma-Aminobutyric Acid; Haloperidol; Humans; Levodopa; Male; Picrotoxin; Rats; Stereotyped Behavior; Valproic Acid | 1982 |
Effects of glycine, chlorpromazine and apomorphine on brain monoamines and free amino acids in rats.
Topics: Amino Acids; Animals; Apomorphine; Binding, Competitive; Biogenic Amines; Brain; Chlorpromazine; Dopamine; Glycine; Levodopa; Rats; Rats, Inbred Strains; Time Factors | 1983 |
Another function of the inner ear: facilitation of the emetic response to poisons.
Topics: Animals; Apomorphine; Dogs; Ear, Inner; Levodopa; Lobeline; Male; Nicotine; Pilocarpine; Poisoning; Vomiting | 1983 |
Effect of chronic levodopa on haloperidol-induced behavioral supersensitivity in the guinea pig.
Topics: Animals; Apomorphine; Behavior, Animal; Carbidopa; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Stereotyped Behavior; Time Factors | 1982 |
Pharmacological comparison of the potential antidepressant UP 614-04 with viloxazine and imipramine; behavioral studies.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Apomorphine; Behavior, Animal; Body Temperature; Drug Interactions; Humans; Imipramine; Levodopa; Male; Mice; Morpholines; Motor Activity; Rats; Reserpine; Stereotyped Behavior; Tetrabenazine; Viloxazine | 1982 |
Stereotypy and dyskinesias provoked in cats differentiate directly and indirectly-acting psychomotor stimulants.
Topics: Animals; Apomorphine; Cats; Dextroamphetamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Nomifensine; Piribedil; Receptors, Dopamine; Stereotyped Behavior | 1982 |
Induction of pituitary tumours and hyperprolactinemia in female rats by estrogens. The effect of apomorphine, reserpine and L-dopa.
Topics: Animals; Apomorphine; Drug Interactions; Estrenes; Estrogens; Female; Levodopa; Organ Size; Pituitary Neoplasms; Prolactin; Rats; Reserpine | 1980 |
Monoamine replacement after reserpine: catecholaminergic agonists restore motor activity but phenylethylamine restores atropine-resistant neocortical low voltage fast activity.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Atropine; Cerebral Cortex; Clonidine; Dextroamphetamine; Evoked Potentials; Levodopa; Lysergic Acid Diethylamide; Motor Activity; Phenethylamines; Rats; Receptors, Cholinergic; Reserpine | 1980 |
Differential effects of dopamine agonists in mature and immature rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Age Factors; Animals; Animals, Newborn; Apomorphine; Benzazepines; Bromocriptine; Dextroamphetamine; Dopamine; Female; Humans; Levodopa; Male; Motor Activity; Rats; Scopolamine; Stereotyped Behavior; Sympathomimetics | 1981 |
Survival of neonatal rats during hypoxia after monoamine stimulating agents.
Topics: 5-Hydroxytryptophan; Animals; Animals, Newborn; Apomorphine; Biogenic Amines; Carbidopa; Female; Hypoxia; Levodopa; Pregnancy; Rats; Rats, Inbred Strains; Time Factors | 1982 |
Catecholamine turnover in the brain and the regulation of luteinizing hormone and corticosterone in starved male rats.
Topics: Albuterol; Animals; Apomorphine; Brain; Catecholamines; Clonidine; Corticosterone; Dopamine; Hypothalamus; Levodopa; Luteinizing Hormone; Male; Median Eminence; Norepinephrine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Starvation | 1982 |
Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Corpus Striatum; Humans; Hydroxydopamines; Levodopa; Male; Rats; Stereotyped Behavior; Substantia Nigra | 1980 |
The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig.
Topics: Animals; Apomorphine; Behavior, Animal; Carbidopa; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Stereotyped Behavior; Time Factors | 1981 |
Properties of rotational behaviour produced by methylxanthine derivatives in mice with unilateral striatal 6-hydroxydopamine-induced lesions.
Topics: Animals; Apomorphine; Corpus Striatum; Humans; Hydroxydopamines; Levodopa; Male; Mice; Receptors, Dopamine; Stereotyped Behavior; Theophylline; Time Factors; Xanthines | 1981 |
The effect of altered dopaminergic activity on food intake in the rat: evidence for an optimal level of dopaminergic activity for behavior.
Topics: Amphetamine; Amphetamines; Animals; Apomorphine; Brain; Cocaine; Dextroamphetamine; Dopamine; Feeding Behavior; Haloperidol; Levodopa; Methylphenidate; Rats; Spiperone | 1980 |
Parkinson's disease: new treatments.
Topics: Acetylcholine; Amantadine; Apomorphine; Bromocriptine; Carbidopa; Counseling; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Manifestations; Parkinson Disease; Physical Therapy Modalities; Receptors, Dopamine; Thalamus | 1981 |
Pharmacological difference of L-dopa, apomorphine, and bromocriptine against metoclopramide.
Topics: Animals; Apomorphine; Bromocriptine; Levodopa; Male; Metoclopramide; Prolactin; Rats; Serotonin | 1981 |
Effects of L-dopa, chlorpromazine and apomorphine on brain monoamines and free amino acids in rats.
Topics: Amino Acids; Animals; Apomorphine; Biogenic Amines; Brain Chemistry; Chlorpromazine; Levodopa; Rats; Rats, Inbred Strains | 1981 |
Adrenergic and dopaminergic modulation of growth hormone and prolactin secretion in normal and tumor bearing human pituitaries in monolayer culture.
Topics: Acromegaly; Adenoma; Adult; Apomorphine; Breast Neoplasms; Bromocriptine; Cells, Cultured; Dopamine; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Sympathomimetics | 1981 |
Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.
Topics: Aged; Apomorphine; Electroconvulsive Therapy; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Prolactin | 1981 |
The role of dopaminergic and serotonergic mechanisms in the development of swimming ability of young rats.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Apomorphine; Haloperidol; Hydroxydopamines; Levodopa; Methysergide; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Serotonin; Swimming; Tryptophan | 1981 |
Effects of neonatal and adult 6-hydroxydopamine treatment on random-interval behavior.
Topics: Aging; Animals; Animals, Newborn; Apomorphine; Brain Chemistry; Catecholamines; Conditioning, Operant; Dose-Response Relationship, Drug; Female; Hydroxydopamines; Levodopa; Male; Mice; Rats; Reinforcement Schedule; Time Factors | 1980 |
Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Desipramine; Dopamine; Feeding Behavior; Hydroxydopamines; Kinetics; Levodopa; Male; Pargyline; Rats | 1980 |
Differential sensitivity of spontaneously hypertensive rats to the hypothermic effect of dopaminergic drugs.
Topics: Animals; Apomorphine; Blood Pressure; Body Temperature; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hypertension; Levodopa; Male; Rats | 1980 |
Relations between dopaminergic and GABAergic mechanisms in avian brain.
Topics: 4-Aminobutyrate Transaminase; Animals; Apomorphine; Brain; Chickens; Ethanolamines; gamma-Aminobutyric Acid; Injections, Intraventricular; Levodopa | 1980 |
Neurochemical and behavioral evidence for a selective presynaptic dopamine receptor agonist.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Levodopa; Motor Activity; Naphthols; Rats; Receptors, Dopamine; Synaptic Membranes; Tetrahydronaphthalenes | 1980 |
Mesencephalic grafts partially restore normal nigral dynorphin levels in 6-hydroxydopamine-lesioned rats treated chronically with L-dihydroxyphenylalanine.
Topics: Amphetamine; Animals; Apomorphine; Brain Tissue Transplantation; Dihydroxyphenylalanine; Dopamine Agents; Dopamine Agonists; Dynorphins; Female; Fetal Tissue Transplantation; Image Processing, Computer-Assisted; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 1995 |
Levodopa-induced dyskinesias are improved by fluoxetine.
Topics: Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Fluoxetine; Humans; Levodopa; Middle Aged | 1995 |
[Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Monoamines; Dopamine; Dopamine Agents; Dopamine Antagonists; Hydroxyindoleacetic Acid; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Tryptophan | 1993 |
Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
Topics: Afferent Pathways; Animals; Apomorphine; Axonal Transport; Brain Mapping; Chorea; Dyskinesia, Drug-Induced; Dystonia; Globus Pallidus; Horseradish Peroxidase; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus; Wheat Germ Agglutinins | 1993 |
[Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary | 1994 |
Early diagnosis of Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Facial Expression; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
Meningioma-induced loss of antiparkinsonian response to levodopa.
Topics: Aged; Apomorphine; Female; Frontal Lobe; Humans; Levodopa; Meningioma; Tomography, X-Ray Computed | 1995 |
Parkinson's disease.
Topics: Apomorphine; Brain; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Movement; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Activity; Receptors, Dopamine; Reserpine | 1994 |
Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors.
Topics: 4-Butyrolactone; Animals; Apomorphine; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Quinolines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereoisomerism | 1993 |
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Immunohistochemistry; Levodopa; Male; Motor Activity; Nerve Fibers; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Interactions between glutamatergic and monoaminergic systems controlling the micturition reflex in the urethane-anesthetized rat.
Topics: Anesthesia; Animals; Apomorphine; Biogenic Monoamines; Dizocilpine Maleate; Female; Fenclonine; Glutamates; Glutamic Acid; Levodopa; Peripheral Nerves; Rats; Rats, Sprague-Dawley; Reflex; Reserpine; Urethane; Urination | 1994 |
3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
Topics: Animals; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Levodopa; Male; Methyldopa; Motor Activity; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra | 1994 |
Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
Topics: Apomorphine; Brain; Functional Laterality; Humans; Levodopa; Motor Skills; Parkinson Disease | 1994 |
The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzazepines; Dopamine; Levodopa; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Sulpiride | 1994 |
[Akinetic crisis in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1994 |
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Topics: Apomorphine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Half-Life; Humans; Levodopa; Middle Aged; Movement; Neuronal Plasticity; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 1994 |
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Topics: Animals; Apomorphine; Autoradiography; Benzazepines; Brain Chemistry; Caudate Nucleus; Dopamine Agents; Female; Infusions, Intravenous; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride | 1993 |
Long-term correction of rat model of Parkinson's disease by gene therapy.
Topics: Animals; Animals, Newborn; Apomorphine; Brain; Cells, Cultured; Dopamine; Drug Carriers; Female; Genetic Therapy; Levodopa; Motor Activity; Muscles; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylethanolamines; Plasmids; Rats; Rats, Sprague-Dawley; Time Factors; Transplantation, Heterotopic; Tyrosine 3-Monooxygenase | 1993 |
Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Topics: 4-Butyrolactone; Adenylyl Cyclases; Amphetamine; Animals; Apomorphine; Biogenic Monoamines; Brain; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Locomotion; Male; Motor Activity; Perfusion; Potassium; Quinolines; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Serotonin; Stereotyped Behavior; Synapses; Tetrahydronaphthalenes; Time Factors; Tritium | 1993 |
Apomorphine increases blood glucose concentrations in Parkinson's disease.
Topics: Aged; Apomorphine; Blood Glucose; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1994 |
Apomorphine and diphasic dyskinesia.
Topics: Aged; Apomorphine; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Topics: Apomorphine; Cell Survival; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; Reaction Time | 1994 |
Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
Topics: Apomorphine; Dose-Response Relationship, Drug; Female; Functional Laterality; Humans; Levodopa; Male; Movement; Parkinson Disease; Time Factors | 1994 |
[Apomorphine test in Parkinson disease--dose and corresponding parameters].
Topics: Adult; Aged; Anthropometry; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Effects of apomorphine and L-dopa on the parkinsonian bladder.
Topics: Aged; Aged, 80 and over; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reflex, Abnormal; Urinary Bladder | 1993 |
The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine; Substance Withdrawal Syndrome | 1993 |
Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
Topics: Aged; Apomorphine; Brain; Dopamine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Motor Cortex; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Regional Blood Flow; Somatosensory Cortex; Tomography, Emission-Computed, Single-Photon | 1993 |
IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Corpus Striatum; Dopamine D2 Receptor Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Pyrrolidines; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1993 |
Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Topics: Adult; Aged; Apomorphine; Female; Follow-Up Studies; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
[Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1996 |
Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Carbidopa; Drug Therapy, Combination; Female; Handwriting; Humans; Levodopa; Male; Microcomputers; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Signal Processing, Computer-Assisted; Treatment Outcome | 1996 |
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Case-Control Studies; Dopamine Agonists; Evoked Potentials, Somatosensory; Humans; Levodopa; Median Nerve; Middle Aged; Parkinson Disease; Psychotic Disorders; Reaction Time; Reference Values | 1995 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Injections; Injections, Intraventricular; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior; Substantia Nigra | 1995 |
[Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Levodopa; Male; Median Nerve; Middle Aged; Motor Skills; Parietal Lobe; Parkinson Disease; Reaction Time; Selegiline; Walking | 1996 |
[The effect on central dopaminergic structures of various hydrazides of phosphorylated carbonic acids and diaziridines].
Topics: Acetates; Animals; Apomorphine; Body Temperature; Catalepsy; Dopamine Agents; Drug Interactions; Haloperidol; Hydrazines; Levodopa; Mice; Stereotyped Behavior | 1996 |
N30 wave of somatosensory evoked potentials in Parkinson's disease: a pharmacological approach.
Topics: Aged; Apomorphine; Dopamine Agents; Dopamine Agonists; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Time Factors | 1996 |
A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease.
Topics: Animals; Apomorphine; Functional Laterality; Hippocampus; Infusions, Parenteral; Levodopa; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation | 1997 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Parkinson Disease | 1997 |
Different effects of levodopa and apomorphine on blink reflex recovery cycle in essential blepharospasm.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Blepharospasm; Blinking; Carbidopa; Dopamine; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Reaction Time; Synaptic Transmission | 1997 |
Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 1997 |
An animal model of copulatory disorder induced by social stress in male mice: effects of apomorphine and L-dopa.
Topics: Aggression; Animals; Apomorphine; Copulation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Levodopa; Male; Mice; Mice, Inbred ICR; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Social Environment; Stress, Psychological | 1997 |
Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Brain; Dopamine; Dopamine Agonists; Drug Synergism; Levodopa; Male; MSH Release-Inhibiting Hormone; Oxidopamine; Pyrrolidinones; Quinpirole; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1997 |
Response of parkinsonian swallowing dysfunction to dopaminergic stimulation.
Topics: Aged; Apomorphine; Barium; Deglutition Disorders; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 1997 |
Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Globus Pallidus; Humans; Intraoperative Period; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques | 1997 |
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Humans; Levodopa; Motor Activity; Parkinson Disease | 1998 |
Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dopamine Agonists; Electrochemistry; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra | 1998 |
The role of dopamine in the expression of morphine withdrawal.
Topics: Adrenergic Agents; Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Antagonists; Hypothermia; Levodopa; Male; Mice; Morphine; Naloxone; Narcotic Antagonists; Oxidopamine; Substance Withdrawal Syndrome | 1998 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Female; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Fibers; Nerve Tissue Proteins; Neuropeptides; Neurotransmitter Agents; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra; Sulpiride; Sympatholytics; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1998 |
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; GTP Cyclohydrolase; Humans; Levodopa; Male; Microdialysis; Neurons; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Proteins; Rotation; Tyrosine 3-Monooxygenase | 1998 |
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Chronotherapy; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps, Implantable; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1998 |
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
Topics: 3T3 Cells; Animals; Antioxidants; Antiparkinson Agents; Apomorphine; Behavior, Animal; Biopterins; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Fibroblasts; Gene Expression Regulation, Enzymologic; Genetic Therapy; Gliosarcoma; GTP Cyclohydrolase; Humans; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Fusion Proteins; Retroviridae; Transformation, Genetic; Transgenes; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 1998 |
The effect of antidepressants on rat aggressive behavior in the electric footshock and apomorphine-induced aggressiveness paradigms.
Topics: Aggression; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Apomorphine; Citalopram; Desipramine; Dopamine Agents; Electroshock; Fluoxetine; Levodopa; Male; Pain Measurement; Rats; Rats, Wistar; Tryptophan | 1998 |
Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Benserazide; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Quinolinic Acid; Rats; Rats, Wistar; Substantia Nigra; Thalamic Nuclei | 1998 |
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1998 |
Dopamine-stimulated sexual behavior is testosterone dependent in mice.
Topics: Aggression; Analysis of Variance; Animals; Apomorphine; Benzazepines; Castration; Dopamine; Dopamine Agonists; Female; Levodopa; Male; Mice; Mice, Mutant Strains; Quinpirole; Sexual Behavior, Animal; Testosterone | 1998 |
Dopamine autoreceptor function is lost in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Autoreceptors; Brain Chemistry; Carbon Radioisotopes; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed | 1999 |
Dopaminergic therapy in acute encephalitis lethargica.
Topics: Acute Disease; Adolescent; Apomorphine; Carbidopa; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Parkinson Disease, Postencephalitic | 1999 |
Worsening of levodopa-induced dyskinesias by motor and mental tasks.
Topics: Analysis of Variance; Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Problem Solving; Severity of Illness Index; Speech; Volition | 1999 |
Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agents; Extracellular Space; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Rats; Rats, Wistar; Rotation; Serotonin; Serotonin Agents; Stereotyped Behavior | 1999 |
Comparison of antipsychotic activity and discriminative stimulus effects of the novel acylprolyltyrosine containing compound, GZR-123, and sulpiride.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Discrimination, Psychological; Dopamine Agents; Dopamine Agonists; Exploratory Behavior; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Proline; Rats; Rats, Wistar; Stereotyped Behavior; Sulpiride; Tyrosine | 1999 |
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Rotation; Substantia Nigra; Sympatholytics | 2000 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Cocaine; Denervation; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Phenotype; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Rotation; Substantia Nigra; Sympatholytics; Tritium | 2000 |
Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
Topics: 1-Methyl-4-phenylpyridinium; Amphetamine; Animals; Apomorphine; Autoradiography; Carrier Proteins; Cocaine; Corpus Striatum; Cytoprotection; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Microinjections; Motor Activity; Nerve Tissue Proteins; Oligonucleotides, Antisense; Oxidopamine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Tritium | 2000 |
Endogenous dopaminergic tone and dopamine agonist action.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Apomorphine; Benzopyrans; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Levodopa; Locomotion; Male; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2000 |
Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Dextroamphetamine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Pyridines; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Rotation | 2000 |
Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Resistance; Globus Pallidus; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra | 2000 |
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Xanthines | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Topics: Aged; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Nitriles; Parkinson Disease | 2001 |
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Topics: Apomorphine; Corpus Striatum; Decision Making; Domperidone; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Guidelines as Topic; Humans; Levodopa; Parkinson Disease; Substantia Nigra; Time Factors | 2001 |
Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Carbidopa; Catecholamines; Clonidine; Dogs; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Growth Hormone; Hypothalamo-Hypophyseal System; Injections, Intraventricular; Levodopa; Male; Neurons; Norepinephrine; Pimozide; Receptors, Adrenergic; Sympathetic Nervous System | 1976 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Idazoxan; Levodopa; Male; Neurologic Examination; Neurons; Norepinephrine; Substantia Nigra | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Transduction, Genetic | 2001 |
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
Topics: Animals; Apomorphine; Chromogranins; DNA, Complementary; Dopamine Agonists; Drug Administration Schedule; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secretogranin II; Sympatholytics; Up-Regulation | 2001 |
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Treatment Outcome | 2002 |
Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Antagonism; Ergolines; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synaptic Transmission | 2002 |
Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Female; Forelimb; Hindlimb; Levodopa; Motor Activity; Motor Skills; Oxidopamine; Psychomotor Performance; Rats; Rats, Long-Evans; Rotation; Stereotyped Behavior; Substantia Nigra | 2002 |
Paradoxical response to apomorphine in a case of atypical parkinsonism.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Treatment Failure | 2002 |
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine | 2002 |
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index | 2003 |
Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Apraxias; Blepharospasm; Dystonia; Eyelids; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2002 |
Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.
Topics: Apomorphine; Cognition; Dopamine; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Task Performance and Analysis; Visual Perception | 2003 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Guanfacine; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-2; Synaptic Transmission; Yohimbine | 2003 |
[Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2003 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Riluzole; Synaptic Transmission | 2003 |
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Apomorphine; Cannabinoids; Carbidopa; Cell Line, Tumor; Dronabinol; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rotation; Substantia Nigra | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
Topics: Aged; Apomorphine; Cognition Disorders; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Humans; Levodopa; Longitudinal Studies; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales | 2003 |
Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Arousal; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Polysomnography; Restless Legs Syndrome; Sleep; Sleep Apnea Syndromes | 2003 |
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Central Nervous System Stimulants; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agonists; Functional Laterality; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Propionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics | 2003 |
The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Benzamides; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Female; Forelimb; Immunohistochemistry; Levodopa; Medial Forebrain Bundle; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Presynaptic | 2003 |
Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzopyrans; Carbidopa; Cocaine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Female; Grooming; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxazines; Pyrroles; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereotyped Behavior | 2003 |
[Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].
Topics: Antiparkinson Agents; Apomorphine; Costs and Cost Analysis; Dopamine Agonists; Drug Costs; Electric Stimulation Therapy; Health Resources; Health Surveys; Hospital Costs; Humans; Infusion Pumps; Insurance, Health, Reimbursement; Italy; Levodopa; National Health Programs; Outpatient Clinics, Hospital; Parkinson Disease | 2003 |
Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Topics: Animals; Apomorphine; Autoradiography; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Receptor, Adenosine A2A; RNA, Messenger; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics; Up-Regulation | 2004 |
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate | 2004 |
PET studies and physiopathology of motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Movement; Parkinson Disease; Tetrabenazine; Tomography, Emission-Computed | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Alpha Rhythm; Antiparkinson Agents; Apomorphine; Beta Rhythm; Biological Clocks; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Neurons; Orphenadrine; Parkinson Disease; Periodicity; Subthalamic Nucleus | 2004 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Lisuride; Parkinson Disease; Pergolide | 2005 |
Acute akinesia in Parkinson disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Akinetic Mutism; Apomorphine; Body Temperature; Cohort Studies; Comorbidity; Dopamine Agents; Dose-Response Relationship, Drug; Drug Resistance; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Mortality; Neuroleptic Malignant Syndrome; Parkinson Disease; Prospective Studies; Recovery of Function; Treatment Failure | 2005 |
Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Female; Gene Expression; Gene Expression Regulation; In Situ Hybridization; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Isoforms; Rats; Rats, Wistar; RNA, Messenger; Rotation; Substantia Nigra; Synaptotagmins; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
Topics: Age of Onset; Antiparkinson Agents; Apomorphine; Basal Ganglia; Calcinosis; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinsonian Disorders | 2005 |
Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding.
Topics: Amphetamine; Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Eating; Feeding Behavior; Hypothalamus; Injections, Intraventricular; Levodopa; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Nomifensine; Signal Transduction; Tyrosine 3-Monooxygenase | 2005 |
Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Caffeine; Central Nervous System Stimulants; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics | 2005 |
Differential effects of cocaine on firing rate and pattern of dopamine neurons: role of alpha1 receptors and comparison with L-dopa and apomorphine.
Topics: Action Potentials; Animals; Apomorphine; Cocaine; Dopamine; Dopamine Agents; Levodopa; Male; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Ventral Tegmental Area | 2006 |
Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cognition Disorders; Deep Brain Stimulation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2006 |
[New types of dopaminergic treatment. The Danish Society of Movement Disorders].
Topics: Antiparkinson Agents; Apomorphine; Delayed-Action Preparations; Dopamine Agonists; Duodenum; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Parkinson Disease; Tablets | 2006 |
Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
Topics: Action Potentials; Adrenergic Agents; Animals; Apomorphine; Brain Injuries; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2006 |
[Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
Topics: Aged; Antiparkinson Agents; Apomorphine; Autonomic Nervous System; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Norepinephrine; Parkinson Disease | 2006 |
Apomorphine-induced myocardial protection is due to antioxidant and not adrenergic/dopaminergic effects.
Topics: Adrenergic Agents; Animals; Antioxidants; Apomorphine; Dopamine Agents; Electrophoresis, Polyacrylamide Gel; Haloperidol; Heart; Hemodynamics; Immunoblotting; Levodopa; Male; Myocardial Reperfusion Injury; Propranolol; Rats; Rats, Sprague-Dawley | 2006 |
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Antiparkinson Agents; Apomorphine; Biological Clocks; Combined Modality Therapy; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2006 |
Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Deep Brain Stimulation; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Humans; Hypokinesia; Infusions, Intravenous; Injections, Subcutaneous; Levodopa; Middle Aged; Neurologic Examination; Optic Atrophy; Parkinson Disease | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior | 2006 |
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Laterality; Levodopa; Male; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2007 |
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Contraindications; Drug Administration Schedule; Drug Therapy, Combination; Humans; Injections; Injections, Subcutaneous; Levodopa; Neurologic Examination; Parkinson Disease | 2008 |
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Endotoxins; Exenatide; Glucagon-Like Peptide-1 Receptor; Levodopa; Locomotion; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Substantia Nigra; Tyrosine 3-Monooxygenase; Venoms | 2008 |
Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Functional Laterality; Gene Expression; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Synaptotagmins; Time Factors | 2008 |
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus | 2008 |
Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response.
Topics: Analysis of Variance; Animals; Apomorphine; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Motor Activity; Multiple System Atrophy; Random Allocation; Rats; Rats, Wistar; Transplantation, Homologous | 2009 |
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microinjections; Organic Chemicals; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Rotation; Serotonin Receptor Agonists; Stereotyped Behavior; Subthalamic Nucleus; Sympathectomy, Chemical; Sympatholytics | 2009 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Chemokine CX3CL1; Disease Models, Animal; DNA Nucleotidylexotransferase; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Levodopa; Male; Mental Disorders; Nerve Tissue Proteins; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reaction Time; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2009 |
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Apomorphine; Brain; Chromosomes, Artificial, Bacterial; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Gene Transfer Techniques; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Mutation, Missense; Neurons; Nomifensine; Parkinson Disease; Protein Serine-Threonine Kinases | 2009 |
Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.
Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dependovirus; Disease Susceptibility; Dopamine; Down-Regulation; Dyskinesia, Drug-Induced; Female; Gene Knockdown Techniques; Levodopa; Microdialysis; Neostriatum; Neurons; Presynaptic Terminals; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Recombination, Genetic; RNA, Small Interfering; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2010 |
Benefit from jejunal levodopa in a patient with apomorphine pump.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Electrophysiological Phenomena; Evoked Potentials; GABA Agonists; Levodopa; Male; Muscimol; Neurons; Parkinson Disease, Secondary; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Substantia Nigra | 2011 |
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Dyskinesia, Drug-Induced; Electrochemistry; Female; Functional Laterality; Levodopa; Oxidopamine; Potassium Chloride; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2011 |
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Postoperative Complications; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Sympatholytics | 2011 |
Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice; Motor Activity; Neurons; Oxidopamine; Rotarod Performance Test; Substantia Nigra | 2012 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Apomorphine injections: predictors of initial common adverse events and long term tolerability.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Time Factors | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Subthalamic activity during diphasic dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cohort Studies; Deep Brain Stimulation; Disease Progression; Dyskinesias; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Theta Rhythm | 2012 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian models.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Dopamine; Immunohistochemistry; Levodopa; Melanocytes; Mice; Monophenol Monooxygenase; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation | 2013 |
[Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2013 |
Claudia Trenkwalder: from bench to bedside (and back again). Interview by Dara Mohammadi.
Topics: Apomorphine; Germany; History, 20th Century; History, 21st Century; Humans; Levodopa; Neurology; Restless Legs Syndrome; Sleep Medicine Specialty; United States | 2013 |
Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Catalepsy; Cysteine Proteinase Inhibitors; Dopamine Agonists; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Reaction Time; Serotonin; Substantia Nigra | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Cost-Benefit Analysis; Deep Brain Stimulation; Drug Administration Schedule; Gels; Germany; Humans; Injections, Subcutaneous; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years | 2015 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Glucose; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Quinolinic Acid; Rats; Rats, Wistar; Striatonigral Degeneration; Touch | 2014 |
Continuous levodopa infusion is better—for now.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Chalcone; Disease Models, Animal; Levodopa; Male; Motor Activity; Olfaction Disorders; Oxidopamine; Parkinson Disease; Quinones; Rats; Receptors, Dopamine D3; Time Factors | 2015 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Indazoles; Levodopa; Locomotion; Male; Movement Disorders; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2015 |
CART modulates the effects of levodopa in rat model of Parkinson's disease.
Topics: Animals; Antibodies; Antiparkinson Agents; Apomorphine; Brain; Dopamine Agonists; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Levodopa; Male; Movement; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2016 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
[Update on Current Care Guideline: Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease | 2016 |
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research | 2016 |
[Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Cost-Benefit Analysis; Deep Brain Stimulation; Economics, Pharmaceutical; Humans; Levodopa; Parkinson Disease; Quality-Adjusted Life Years | 2016 |
Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Topics: Animals; Apomorphine; Dendritic Spines; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundle; Neurons; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Statistics, Nonparametric; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Levodopa; Motor Cortex; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, GABA; RNA, Messenger; Sympatholytics; Tandem Mass Spectrometry | 2017 |
Use of advanced therapies for Parkinson's disease in Norway.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic | 2017 |
Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
Topics: Animals; Apomorphine; Basal Ganglia; Cerebral Cortex; Dose-Response Relationship, Drug; Levodopa; Male; Nerve Net; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar | 2017 |
The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
Topics: Aged; Apomorphine; Dopamine Agents; Female; Follow-Up Studies; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Placebo Effect | 2017 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electroacupuncture; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Motor Cortex; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Methamphetamine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley | 2018 |
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden | 2018 |
Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.
Topics: Antiparkinson Agents; Apomorphine; Cognition; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Levodopa; Male; Mental Disorders; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2019 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians' | 2019 |
Analyzing Apomorphine-Mediated Effects in a Cell Model for Parkinson's Disease with Partial Least Squares Structure Equation Modeling.
Topics: Apomorphine; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Least-Squares Analysis; Levodopa; Male; Microarray Analysis; Nausea; Parkinson Disease; Transcriptome | 2020 |
Clinical Trial Highlights - Infusion Therapies.
Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease | 2020 |
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
Topics: Amantadine; Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gonorrhea; Humans; Levodopa; Middle Aged; Parkinson Disease; Sexual Dysfunctions, Psychological; Tetrahydronaphthalenes; Thiophenes | 2020 |
L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
Topics: Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Substantia Nigra | 2020 |
[Movement Disorders: What Are You Doing? What Can We Do?]
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Essential Tremor; Humans; Levodopa; Parkinson Disease | 2020 |
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Prospective Studies | 2020 |
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal | 2021 |
Device-aided therapies for advanced Parkinson disease: insights from an international survey.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2021 |
Apomorphine hydrochloride: a sublingual tablet for the OFF episodes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Middle Aged; Parkinson Disease; Tablets | 2021 |
Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Registries; Risk Factors; Thailand; Time and Motion Studies; Treatment Outcome; Withholding Treatment | 2021 |
Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Powders | 2022 |
Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.
Topics: Antiparkinson Agents; Apomorphine; Feasibility Studies; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2023 |
Task Specific Tremor in Parkinson's Disease Responds to Apomorphine.
Topics: Apomorphine; Dopamine; Humans; Levodopa; Parkinson Disease; Tremor | 2023 |
Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |